

CITATION REPORT

List of articles citing

Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease

DOI: 10.1038/77528

Nature Medicine, 2000, 6, 797-801.

Source: <https://exaly.com/paper-pdf/31430115/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
916	Dominant ataxias. 242-283		
915	Molecular genetics: unmasking polyglutamine triggers in neurodegenerative disease. 2000 , 1, 109-15		322
914	Huntington's disease: the challenge for cell biologists. 2000 , 10, 531-6		201
913	Intranuclear huntingtin increases the expression of caspase-1 and induces apoptosis. 2000 , 9, 2859-67		94
912	Improving Energy, Transport and Communications Infrastructure: the Case of Sri Lanka. 2000 , 7, 55-69		1
911	Morbus Huntington - a human genetic model disease. 2000 , 91, 90-6		1
910	Neuronal apoptosis as a therapeutic target in neurodegenerative disease. 2000 , 10, 1493-1518		11
909	Interactions of tetracyclines with RNA. 2001 , 177-196		
908	Inhibition of matrix metalloproteinases (MMPs) by tetracyclines. 2001 , 267-281		7
907	Minocycline provides neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia. 2001 , 166, 7527-33		459
906	A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington's disease. 2001 , 171, 351-60		87
905	Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease. 2001 , 8, 479-91		237
904	Inflammation contributes to the postponed ischemic neuronal damage following treatment with a glutamate antagonist in rats. 2001 , 298, 103-6		20
903	Minocycline blocks nitric oxide-induced neurotoxicity by inhibition p38 MAP kinase in rat cerebellar granule neurons. 2001 , 315, 61-4		118
902	Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model. 2001 , 315, 149-53		143
901	Huntington's disease: new hope for therapeutics. 2001 , 24, S32-8		36
900	Huntington's disease: new hope for therapeutics. 2001 , 24, 32-38		70

899	Evaluation of R6/2 HD transgenic mice for therapeutic studies in Huntington's disease: behavioral testing and impact of diabetes mellitus. 2001 , 126, 185-95	109
898	Gene expression profiling in the post-mortem human brain--no cause for dismay. 2001 , 22, 79-94	137
897	Anti-amyloidogenic activity of tetracyclines: studies in vitro. 2001 , 487, 404-7	175
896	Neuroprotective therapy for Huntington's disease: new prospects and challenges. 2001 , 1, 111-8	11
895	Antisense strategies for the treatment of neurological disease. 2001 , 11, 547-562	
894	Inhibition of trypsin-like cysteine proteinases (gingipains) from <i>Porphyromonas gingivalis</i> by tetracycline and its analogues. 2001 , 45, 2871-6	37
893	Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. 2001 , 21, 2580-8	796
892	Minocycline Reduces Traumatic Brain Injury-mediated Caspase-1 Activation, Tissue Damage, and Neurological Dysfunction. 2001 , 48, 1393-1401	179
891	Minocycline reduces traumatic brain injury-mediated caspase-1 activation, tissue damage, and neurological dysfunction. 2001 , 48, 1393-9; discussion 1399-401	238
890	Minocycline Reduces Traumatic Brain Injury-mediated Caspase-1 Activation, Tissue Damage, and Neurological Dysfunction. 2001 ,	
889	Activated microglia: the silent executioner in neurodegenerative disease?. 2001 , 1, 303-5	16
888	Tetracycline derivatives and ceftriaxone, a cephalosporin antibiotic, protect neurons against apoptosis induced by ionizing radiation. 2001 , 78, 1409-14	75
887	Nitric oxide and nitric oxide synthase in Huntington's disease. 2001 , 64, 99-107	68
886	Late-onset metachromatic leukodystrophy clinically presenting as isolated peripheral neuropathy: Compound heterozygosity for the IVS2+1G- β mutation and a newly identified missense mutation (Thr408Ile) in a Spanish family. 2001 , 50, 108-112	22
885	Familial frontotemporal dementia and parkinsonism with a novel mutation at an intron 10+11-splice site in the tau gene. 2001 , 50, 117-20	55
884	Progressive mitochondrial disease resulting from a novel missense mutation in the mitochondrial DNA ND3 gene. 2001 , 50, 104-7	79
883	Dichloroacetate exerts therapeutic effects in transgenic mouse models of Huntington's disease. 2001 , 50, 112-7	72
882	Comparative analysis of superoxide dismutase activity between acute pharmacological models and a transgenic mouse model of Huntington's disease. 2001 , 26, 419-24	50

881	Modeling Huntington's disease in cells, flies, and mice. 2001 , 23, 21-51	55
880	Therapeutic opportunities in polyglutamine disease. <i>Nature Medicine</i> , 2001 , 7, 419-23	50.5 65
879	Huntington's disease. 2001 , 1, 142-152	33
878	Similarities between spinocerebellar ataxia type 7 (SCA7) cell models and human brain: proteins recruited in inclusions and activation of caspase-3. 2001 , 10, 2569-79	75
877	Caspases in Huntington's disease. 2001 , 7, 480-9	47
876	Neuronal Death by Accident or by Design. 2001 ,	
875	Genetic testing in spinocerebellar ataxias: defining a clinical role. 2001 , 58, 191-5	42
874	Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. 2001 , 98, 14669-74	647
873	Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. 2001 , 10, 1049-59	344
872	Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease. 2001 , 10, 1829-45	206
871	Novel therapies in the search for a cure for Huntington's disease. 2001 , 98, 3-4	38
870	Modulation of release of proinflammatory bacterial compounds by antibacterials: potential impact on course of inflammation and outcome in sepsis and meningitis. 2002 , 15, 95-110	189
869	Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease. 2002 , 99, 10671-6	239
868	Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity. 2002 , 99, 1002-7	130
867	Tetracyclines affect prion infectivity. 2002 , 99, 10849-54	166
866	Alterations in the mouse and human proteome caused by Huntington's disease. 2002 , 1, 366-75	66
865	Toxicity of CSF in motor neurone disease: a potential route to neuroprotection. 2002 , 125, 693-4	16
864	Minocycline prevents neurotoxicity induced by cerebrospinal fluid from patients with motor neurone disease. 2002 , 125, 722-31	122

863	Practical approaches to neurogenetic disease. 2002 , 22, 297-304		19
862	Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. 2002 , 125, 1297-308		373
861	Protein conformational misfolding and amyloid formation: characteristics of a new class of disorders that include Alzheimer's and Prion diseases. 2002 , 9, 1751-62		42
860	Maintained improvement with minocycline of a patient with advanced Huntington's disease. 2002 , 16, 393-4		28
859	Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease. 2002 , 11, 1939-51		108
858	Calcium-dependent cleavage of endogenous wild-type huntingtin in primary cortical neurons. 2002 , 277, 39594-8		63
857	Huntington's disease. 2002 , 1896-1910		
856	Minocycline delays disease onset and mortality in a transgenic model of ALS. 2002 , 13, 1067-70		256
855	Recent advances in Huntington's disease: implications for experimental therapeutics. <i>Current Opinion in Neurology</i> , 2002 , 15, 483-9	7.1	33
854	Caspase inhibitors as anti-inflammatory and antiapoptotic agents. 2002 , 39, 1-72		20
853	Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. 2002 , 22, 1763-71		1053
852	Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. 2002 , 10, 268-78		352
851	Neuroprotection in Huntington's disease: Minocycline. 2002 , 12, 367-368		
850	Galantamine reduces behavioral and psychotic disturbances and behavior-related caregiver burden in mild-to-moderate Alzheimer's disease. 2002 , 12, 368-369		
849	Mutant huntingtin aggregates do not sensitize cells to apoptotic stressors. 2002 , 515, 61-5		8
848	Therapies in amyotrophic lateral sclerosis-beyond riluzole. 2002 , 2, 302-9		22
847	Evidence for a role for transglutaminase in Huntington's disease and the potential therapeutic implications. 2002 , 40, 31-6		53
846	Mouse models of Huntington's disease. 2002 , 23, 32-9		247

845	Therapeutic effects of cystamine in a murine model of Huntington's disease. 2002 , 22, 8942-50	280
844	Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. 2002 , 22, 1592-9	348
843	Implications physiopathologiques des altérations des gènes impliqués dans la régulation de la mort cellulaire. 2002 , 18, 861-873	
842	Lessons from animal models of Huntington's disease. 2002 , 18, 202-9	248
841	Altered neuronal nitric oxide synthase expression contributes to disease progression in Huntington's disease transgenic mice. 2002 , 939, 76-86	53
840	Inhibition of autoimmune encephalomyelitis by a tetracycline. 2002 , 51, 215-23	254
839	Minocycline markedly protects the neonatal brain against hypoxic-ischemic injury. 2002 , 52, 54-61	280
838	Effect of minocycline in experimental autoimmune encephalomyelitis. 2002 , 52, 689-90; author reply 690	41
837	Studies on neuronal death in the mouse model of Niemann-Pick C disease. 2002 , 68, 738-44	43
836	Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease. 2002 , 17, 748-57	92
835	Spinocerebellar degenerations: an update. 2002 , 2, 331-41	1
834	Transgenic mouse models of neurodegenerative disease: opportunities for therapeutic development. 2002 , 2, 457-64	44
833	Enhancement of the discriminative stimulus effects of phencyclidine by the tetracycline antibiotics doxycycline and minocycline in rats. 2002 , 160, 331-6	14
832	Riluzole and olanzapine in Huntington's disease. 2002 , 9, 183-4	11
831	Zolpidem in progressive supranuclear palsy. 2002 , 9, 184-5	26
830	Extensive and divergent circadian gene expression in liver and heart. 2002 , 417, 78-83	1235
829	Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. 2002 , 417, 74-8	937
828	A bivalent Huntingtin binding peptide suppresses polyglutamine aggregation and pathogenesis in <i>Drosophila</i> . 2002 , 30, 367-76	151

827	Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. <i>Nature Medicine</i> , 2002 , 8, 143-9 ^{50.5}	343
826	Cytochrome C and caspase-9 expression in Huntington's disease. 2002 , 1, 183-95	94
825	Huntington's disease. 2003 , 4, 7-20	61
824	MTS-conjugated-antiactive caspase 3 antibodies inhibit actinomycin D-induced apoptosis. 2003 , 8, 631-7	21
823	Huntington's disease: a decade beyond gene discovery. 2003 , 3, 279-84	8
822	Excitotoxicity in Huntington disease. 2003 , 3, 121-128	16
821	Identifying new therapeutics for Huntington's disease. 2003 , 3, 179-186	1
820	Plans for HDBase research community website for Huntington's Disease. 2003 , 3, 197-217	6
819	The basic aspects of therapeutics in amyotrophic lateral sclerosis. 2003 , 98, 379-414	72
818	Suppression of activated microglia promotes survival and function of transplanted oligodendroglial progenitors. 2003 , 41, 191-8	59
817	Minocycline enhances MPTP toxicity to dopaminergic neurons. 2003 , 74, 278-85	125
816	Role of proteolysis in polyglutamine disorders. 2003 , 74, 406-16	71
815	Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. 2003 , 53, 267-70	164
814	Efficient three-drug cocktail for disease induced by mutant superoxide dismutase. 2003 , 53, 429-36	119
813	Intracerebral hemorrhage induces macrophage activation and matrix metalloproteinases. 2003 , 53, 731-42	309
812	Of mice and men: reconciling preclinical ALS mouse studies and human clinical trials. 2003 , 53, 423-6	69
811	Minocycline and doxycycline are not beneficial in a model of Huntington's disease. 2003 , 54, 186-96	145
810	Minocycline is not beneficial in a phenotypic mouse model of Huntington's disease. 2003 , 54, 841-2	24

809	Minocycline is protective in a mouse model of Huntington's disease. 2003 , 54, 841; author reply 842-3	52
808	Reply. 2003 , 54, 842-843	11
807	Liquid chromatographic determination of minocycline in brain-to-plasma distribution studies in the rat. 2003 , 791, 337-43	98
806	Pro-apoptotic protein kinase C delta is associated with intranuclear inclusions in a transgenic model of Huntington's disease. 2003 , 87, 395-406	19
805	Inclusion formation in Huntington's disease R6/2 mouse muscle cultures. 2003 , 87, 1-6	35
804	Sequential activation of individual caspases, and of alterations in Bcl-2 proapoptotic signals in a mouse model of Huntington's disease. 2003 , 87, 1184-92	55
803	Modelling brain diseases in mice: the challenges of design and analysis. 2003 , 4, 296-307	68
802	Targeting programmed cell death in neurodegenerative diseases. 2003 , 4, 365-75	432
801	Minocycline-induced activation of tetracycline-responsive promoter. 2003 ,	1
800	Cystamine inhibits caspase activity. Implications for the treatment of polyglutamine disorders. 2003 , 278, 3825-30	131
799	Amyotrophic lateral sclerosis: progress and prospects for treatment. 2003 , 63, 289-310	20
798	Minocycline-induced activation of tetracycline-responsive promoter. 2003 , 352, 155-8	13
797	Role of NR2B-type NMDA receptors in selective neurodegeneration in Huntington disease. 2003 , 24, 1113-21	92
796	Minocycline blocks 6-hydroxydopamine-induced neurotoxicity and free radical production in rat cerebellar granule neurons. 2003 , 72, 1635-41	49
795	Apoptosis in Huntington's disease. 2003 , 27, 255-65	133
794	Early microglial activation following neonatal excitotoxic brain damage in mice: a potential target for neuroprotection. 2003 , 121, 619-28	173
793	Future directions in research with presymptomatic individuals carrying the gene for Huntington's disease. 2003 , 59, 331-8	16
792	Novel anti-inflammatory therapy for Parkinson's disease. 2003 , 24, 395-401	278

791	Overexpression and nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase in a transgenic mouse model of Huntington's disease. 2003 , 22, 285-97	57
790	Recent advances in understanding the pathogenesis of polyglutamine diseases: involvement of molecular chaperones and ubiquitin-proteasome pathway. 2003 , 26, 95-101	47
789	Targeting aggregation in the development of therapeutics for the treatment of Huntington's disease and other polyglutamine repeat diseases. 2003 , 7, 201-13	15
788	Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. 2003 , 100, 2041-6	734
787	Molecular Biology of Huntington's Disease (HD) and HD-Like Disorders. 2003 , 365-383	4
786	Leukemia inhibitory factor promotes recovery of locomotor function following spinal cord injury in the mouse. 2003 , 20, 1215-22	40
785	Prospects for the pharmacotherapy of amyotrophic lateral sclerosis : old strategies and new paradigms for the third millennium. 2003 , 17, 699-717	19
784	MAPKs: new targets for neurodegeneration. 2003 , 7, 187-200	88
783	Why minocycline is helpful in Huntington's disease. 2003 , 17, 461	6
782	Inhibition of microglial activation attenuates the development but not existing hypersensitivity in a rat model of neuropathy. 2003 , 306, 624-30	655
781	Mismatch repair gene Msh2 modifies the timing of early disease in Hdh(Q111) striatum. 2003 , 12, 273-81	171
780	The use of transgenic and knock-in mice to study Huntington's disease. 2003 , 100, 276-86	49
779	A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila. 2003 , 100, 5950-5	159
778	4'-iodo-4'-deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: screening for TTR fibril disrupters. 2003 , 17, 803-9	103
777	A twofold increase in BRCA mutation related prostate cancer among Ashkenazi Israelis is not associated with distinctive histopathology. 2003 , 40, 787-92	69
776	Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice. 2003 , 126, 1628-37	310
775	Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease. 2003 , 100, 10483-7	364
774	Minocycline for Huntington's disease: an open label study. 2003 , 60, 883-4	74

773	Caspase-1 and caspase-8 cleave and inactivate cellular parkin. 2003 , 278, 23376-80		60
772	Early and reversible neuropathology induced by tetracycline-regulated lentiviral overexpression of mutant huntingtin in rat striatum. 2003 , 12, 2827-36		70
771	Huntington's disease: prospects for neuroprotective therapy 10 years after the discovery of the causative genetic mutation. <i>Current Opinion in Neurology</i> , 2003 , 16, 501-6	7.1	14
770	Experimental therapeutics in Huntington's disease. <i>Current Opinion in Neurology</i> , 2003 , 16, 465-470	7.1	6
769	. <i>Current Opinion in Neurology</i> , 2003 , 16, 501-506	7.1	10
768	Neuroprotection in Huntington's [correction of Hungtinton's] disease. 2003 , 26, 223-4; author reply 224		1
767	Neuroprotection in Hungtinton's Disease: RESPONSE FROM THE AUTHORS. 2003 , 26, 224		
766	Clinical and research advances in Huntington's disease. 2003 , 30 Suppl 1, S45-52		3
765	Minocycline and other tetracycline derivatives: a neuroprotective strategy in Parkinson's disease and Huntington's disease. 2003 , 26, 18-23		44
764	Experimental therapeutics in Huntington's disease: are models useful for therapeutic trials?. <i>Current Opinion in Neurology</i> , 2003 , 16, 465-70	7.1	37
763	Oxidative Stress and Huntington's Disease. 2003 ,		
762	Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. 2003 , 23, 9418-27		591
761	[C. elegans as a model for human inherited degenerative diseases]. 2003 , 19, 1218-25		4
760	Cell cycle regulators in the neuronal death pathway of amyotrophic lateral sclerosis caused by mutant superoxide dismutase 1. 2003 , 23, 2131-40		143
759	Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease. 2003 , 23, 2193-202		212
758	Huntingtin in health and disease. 2003 , 111, 299-302		81
757	Apoptosis in acute and chronic neurological disorders. 2004 , 9, 1567-76		53
756	. 2004 ,		2

755	Prospects for neuroprotection in multiple sclerosis. 2004 , 9, 864-72	27
754	Apoptosis: a key in neurodegenerative disorders. 2004 , 1, 355-71	79
753	Mouse models of triplet repeat diseases. 2004 , 277, 3-15	1
752	Potential new strategies to prevent the development of diabetic retinopathy. 2004 , 13, 189-98	31
751	Neurotransmitter receptor analysis in transgenic mouse models. 2004 , 277, 231-60	12
750	Minocycline: neuroprotective mechanisms in Parkinson's disease. 2004 , 10, 679-86	88
749	Striatal cells from mutant huntingtin knock-in mice are selectively vulnerable to mitochondrial complex II inhibitor-induced cell death through a non-apoptotic pathway. 2004 , 13, 669-81	72
748	CORRECTION. 2004 , 41, 51-51	1
747	Activation of the I κ B kinase complex and nuclear factor- κ B contributes to mutant huntingtin neurotoxicity. 2004 , 24, 7999-8008	168
746	Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury. 2004 , 24, 2182-90	407
745	Congo red, doxycycline, and HSP70 overexpression reduce aggregate formation and cell death in cell models of oculopharyngeal muscular dystrophy. 2004 , 41, 47-51	41
744	Minocycline up-regulates Bcl-2 and protects against cell death in mitochondria. 2004 , 279, 19948-54	203
743	Trinucleotide repeats and neurodegenerative disease. 2004 , 127, 2385-405	128
742	An investigation of the neuroprotective effects of tetracycline derivatives in experimental models of retinal cell death. 2004 , 66, 1113-22	49
741	Trinucleotide Repeat Protocols. 2004 ,	3
740	Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis. 2004 , 62, 1845-7	114
739	Mutant huntingtin affects the rate of transcription of striatum-specific isoforms of phosphodiesterase 10A. 2004 , 20, 3351-63	68
738	Kennedy's disease: pathogenesis and clinical approaches. 2004 , 34, 279-86	33

737	The arachidonic acid 5-lipoxygenase inhibitor nordihydroguaiaretic acid inhibits tumor necrosis factor alpha activation of microglia and extends survival of G93A-SOD1 transgenic mice. 2004 , 91, 133-43	112
736	Minocycline inhibits apoptotic cell death via attenuation of TNF-alpha expression following iNOS/NO induction by lipopolysaccharide in neuron/glia co-cultures. 2004 , 91, 568-78	120
735	Minocycline prevents glutamate-induced apoptosis of cerebellar granule neurons by differential regulation of p38 and Akt pathways. 2004 , 91, 1219-30	133
734	Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease. 2004 , 19, 3266-76	141
733	Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. <i>Nature Medicine</i> , 2004 , 10, 148-54	50.5 609
732	Mice overexpressing human caspase 3 appear phenotypically normal but exhibit increased apoptosis and larger lesion volumes in response to transient focal cerebral ischaemia. 2004 , 11, 1102-11	23
731	Neuroprotective effects of M826, a reversible caspase-3 inhibitor, in the rat malonate model of Huntington's disease. 2004 , 141, 689-97	42
730	Differential expression of chemokines and chemokine receptors during microglial activation and inhibition. 2004 , 149, 1-9	93
729	Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis. 2004 , 3, 291-304	842
728	Disease modification in Parkinson's disease. 2004 , 3, 362-8	58
727	The promise of minocycline in neurology. 2004 , 3, 744-51	390
726	Lack of evidence of direct mitochondrial involvement in the neuroprotective effect of minocycline. 2004 , 505, 111-9	26
725	New perspectives on vitamin E: gamma-tocopherol and carboxyethylhydroxychroman metabolites in biology and medicine. 2004 , 36, 1-15	233
724	The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease. 2004 , 1019, 246-54	89
723	A novel action of minocycline: inhibition of human immunodeficiency virus type 1 infection in microglia. 2004 , 10, 284-92	63
722	Huntington's disease: pathomechanism and therapeutic perspectives. 2004 , 111, 1485-94	58
721	Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease. 2003 , 86, 267-72	49
720	Minocycline inhibits neuronal death and glial activation induced by beta-amyloid peptide in rat hippocampus. 2004 , 48, 85-90	109

719	Failure of neuronal protection by inhibition of glial activation in a rat model of striatonigral degeneration. 2004 , 78, 87-91	26
718	Minocycline in Huntington's disease: a pilot study. 2004 , 19, 692-5	91
717	Liquid chromatographic assay for riluzole in mouse plasma and central nervous system tissues. 2004 , 803, 305-9	21
716	Preclinical studies: how much can we rely on?. 2004 , 5 Suppl 1, 22-5	7
715	Minocycline inhibits contusion-triggered mitochondrial cytochrome c release and mitigates functional deficits after spinal cord injury. 2004 , 101, 3071-6	285
714	Huntingtin and its role in neuronal degeneration. 2004 , 10, 467-75	81
713	Novel sesquiterpenoid matrix metalloproteinase-3 inhibitors from an acid mine waste extremophile. 2004 , 67, 1392-5	30
712	Minocycline inhibits apoptosis and inflammation in a rat model of ischemic renal injury. 2004 , 287, F760-6	95
711	Berkeleydione and berkeleytrione, new bioactive metabolites from an acid mine organism. 2004 , 6, 1049-52	78
710	Minocycline inhibits caspase activation and reactivation, increases the ratio of XIAP to smac/DIABLO, and reduces the mitochondrial leakage of cytochrome C and smac/DIABLO. 2004 , 43, 865-74	113
709	The paradigm of Huntington's disease: therapeutic opportunities in neurodegeneration. 2004 , 1, 128-38	52
708	Using advances in neuroimaging to detect, understand, and monitor disease progression in Huntington's disease. 2004 , 1, 263-72	76
707	Translating therapies for Huntington's disease from genetic animal models to clinical trials. 2004 , 1, 298-306	60
706	Mechanisms of cell death in polyglutamine expansion diseases. 2004 , 4, 85-90	41
705	Minocycline delays photoreceptor death in the rds mouse through a microglia-independent mechanism. 2004 , 78, 1077-84	54
704	Optimal delivery of minocycline to the brain: implication for human studies of acute neuroprotection. 2004 , 186, 248-51	104
703	Blockade of quinolinic acid-induced neurotoxicity by pyruvate is associated with inhibition of glial activation in a model of Huntington's disease. 2004 , 187, 150-9	47
702	Minocycline worsens hypoxic-ischemic brain injury in a neonatal mouse model. 2004 , 189, 58-65	154

701	Rise and fall of minocycline in neuroprotection: need to promote publication of negative results. 2004 , 189, 1-4	70
700	Anti-inflammatory effects of tocopherol metabolites. 2004 , 319, 1047-52	76
699	Neuroprotection by tetracyclines. 2004 , 25, 609-12	169
698	Minocycline reduces the lipopolysaccharide-induced inflammatory reaction, peroxynitrite-mediated nitration of proteins, disruption of the blood-brain barrier, and damage in the nigral dopaminergic system. 2004 , 16, 190-201	158
697	Anti-inflammatory treatment with acetylsalicylate or rofecoxib is not neuroprotective in Huntington's disease transgenic mice. 2004 , 17, 319-25	36
696	Clinical potential of minocycline for neurodegenerative disorders. 2004 , 17, 359-66	134
695	A novel systemically active caspase inhibitor attenuates the toxicities of MPTP, malonate, and 3NP in vivo. 2004 , 17, 250-9	63
694	Minocycline attenuates gentamicin induced hair cell loss in neonatal cochlear cultures. 2004 , 197, 11-8	49
693	Why minocycline can cause systemic lupus - a hypothesis and suggestions for therapeutic interventions based on it. 2004 , 63, 31-4	8
692	The potential of minocycline for neuroprotection in human neurologic disease. 2004 , 27, 293-8	99
691	17 Beta-estradiol regulates nNOS and eNOS activity in the hippocampus. 2004 , 15, 89-93	54
690	Aging in individuals with the FMR1 mutation. 2004 , 109, 154-64	127
689	Neuroprotection in Huntington's disease: a 2-year study on minocycline. 2004 , 19, 337-42	72
688	Minocycline protects PC12 cells from ischemic-like injury and inhibits 5-lipoxygenase activation. 2004 , 15, 2181-4	59
687	Huntington's disease: present treatments and future therapeutic modalities. 2004 , 19, 51-62	59
686	Microglia-targeted pharmacotherapy in retinal neurodegenerative diseases. 2004 , 5, 619-27	54
685	Strategies to promote neural repair and regeneration after spinal cord injury. 2005 , 30, S3-13	60
684	Anti-inflammatory properties of antibiotics other than macrolides. 2005 , 247-267	2

683	Neurodegenerative Disorders as Proteinopathies: Phenotypic Relationships. 2005 , 1-10		
682	Caspases; Modulators of Apoptosis and Cytokine Maturation ¶Targets for Novel Therapies. 2005 , 79-106		
681	Minimizing the release of proinflammatory and toxic bacterial products within the host: a promising approach to improve outcome in life-threatening infections. 2005 , 44, 1-16		31
680	Antioxidant properties of minocycline: neuroprotection in an oxidative stress assay and direct radical-scavenging activity. 2005 , 94, 819-27		235
679	Treatment of YAC128 mice and their wild-type littermates with cystamine does not lead to its accumulation in plasma or brain: implications for the treatment of Huntington disease. 2005 , 94, 1087-101		49
678	Inhibition of thrombin-induced microglial activation and NADPH oxidase by minocycline protects dopaminergic neurons in the substantia nigra in vivo. 2005 , 95, 1755-65		99
677	Minocycline blocks bilirubin neurotoxicity and prevents hyperbilirubinemia-induced cerebellar hypoplasia in the Gunn rat. 2005 , 22, 21-7		55
676	Gene-environment interactions, neuronal dysfunction and pathological plasticity in Huntington's disease. 2005 , 32, 1007-19		43
675	Characterization of the caspase cascade in a cell culture model of SOD1-related familial amyotrophic lateral sclerosis: expression, activation and therapeutic effects of inhibition. 2005 , 31, 467-85		28
674	Effects of minocycline on Fas-mediated fulminant hepatitis in mice. 2005 , 144, 275-82		20
673	Doxycycline attenuates and delays toxicity of the oculopharyngeal muscular dystrophy mutation in transgenic mice. <i>Nature Medicine</i> , 2005 , 11, 672-7	50.5	125
672	Therapeutics development for triplet repeat expansion diseases. 2005 , 6, 756-65		127
671	Doxycycline reduces cleaved caspase-3 and microglial activation in an animal model of neonatal hypoxia-ischemia. 2005 , 25, 314-24		71
670	Minocycline protects against permanent cerebral ischemia in wild type but not in matrix metalloprotease-9-deficient mice. 2005 , 25, 460-7		107
669	Development of novel therapies for Huntington's disease: hope and challenge. 2005 , 26, 129-42		11
668	Minocycline inhibits oxidative stress and decreases in vitro and in vivo ischemic neuronal damage. 2005 , 1044, 8-15		108
667	Activation of the stress-activated MAP kinase, p38, but not JNK in cortical motor neurons during early presymptomatic stages of amyotrophic lateral sclerosis in transgenic mice. 2005 , 1045, 185-98		58
666	The powerhouse takes control of the cell: is the mitochondrial permeability transition a viable therapeutic target against neuronal dysfunction and death?. 2005 , 38, 687-97		89

665	Matrix metalloproteinases and free radicals in cerebral ischemia. 2005 , 39, 71-80	203
664	Minocycline fails to protect cerebellar granular cell cultures against malonate-induced cell death. 2005 , 20, 384-91	27
663	Additive effect of the combination of glatiramer acetate and minocycline in a model of MS. 2005 , 158, 213-21	91
662	Effective combination of minocycline and interferon-beta in a model of multiple sclerosis. 2005 , 165, 83-91	71
661	Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice. 2005 , 490, 354-70	196
660	Reply: Huntington's disease and minocycline. 2005 , 20, 511-511	
659	Huntington's disease and minocycline. 2005 , 20, 510-511	7
658	A novel therapeutic strategy for polyglutamine diseases by stabilizing aggregation-prone proteins with small molecules. 2005 , 83, 343-52	63
657	Molecular targets in spinal cord injury. 2005 , 83, 657-71	56
656	Expression pattern of apoptosis-related markers in Huntington's disease. 2005 , 109, 321-8	74
655	Minocycline in amyotrophic lateral sclerosis: a pilot study. 2005 , 26, 285-7	33
654	Apoptosis in health, disease, and therapy: overview and methodology. 2005 , 1-48	2
653	Neurodegeneration. 2005 , 335-355	
652	. 2005 ,	8
651	Apoptosis in neurodegenerative diseases. 2005 , 80-93	
650	Huntington's disease. 2005 , 847-860	1
649	Multiple Sclerosis: Looking beyond Autoimmunity. 2005 , 98, 303-306	12
648	Computational Modeling of Biological Processes with Petri Net-Based Architecture. 2005 , 179-242	4

647	Minocycline attenuates T cell and microglia activity to impair cytokine production in T cell-microglia interaction. 2005 , 78, 135-43	110
646	Neuroprotection in Huntington's Disease. 2005 , 2, 143-147	
645	Progression of structural neuropathology in preclinical Huntington's disease: a tensor based morphometry study. 2005 , 76, 650-5	136
644	Neuroprotective and anti-human immunodeficiency virus activity of minocycline. 2005 , 293, 2003-11	176
643	Inactivation of Drosophila Apaf-1 related killer suppresses formation of polyglutamine aggregates and blocks polyglutamine pathogenesis. 2005 , 14, 357-72	53
642	Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. 2005 , 280, 556-63	347
641	Chlortetracycline and demeclocycline inhibit calpains and protect mouse neurons against glutamate toxicity and cerebral ischemia. 2005 , 280, 33811-8	57
640	Beyond the signal sequence: protein routing in health and disease. 2005 , 26, 479-503	68
639	Emerging chemotherapeutic strategies for Huntington's disease. 2005 , 10, 345-63	21
638	Microglia Kv1.3 channels contribute to their ability to kill neurons. 2005 , 25, 7139-49	160
637	Dysregulation of receptor interacting protein-2 and caspase recruitment domain only protein mediates aberrant caspase-1 activation in Huntington's disease. 2005 , 25, 11645-54	41
636	Minocycline partially inhibits caspase-3 activation and photoreceptor degeneration after photic injury. 2005 , 37, 202-13	19
635	TransMabs: cell-penetrating antibodies, the next generation. 2005 , 5, 237-41	22
634	Minocycline as a neuroprotective agent. 2005 , 11, 308-22	210
633	New horizons for primary intracerebral hemorrhage treatment: experience from preclinical studies. 2005 , 27, 268-79	234
632	Treatment of multiple sclerosis: beyond the NICE guidelines. 2005 , 98, 373-8	10
631	Multiple sclerosis: looking beyond autoimmunity. 2005 , 98, 303-6	11
630	Intrathecal minocycline attenuates peripheral inflammation-induced hyperalgesia by inhibiting p38 MAPK in spinal microglia. 2005 , 22, 2431-40	208

629	Huntington's disease and related disorders. 2005 , 28, 275-90, x	15
628	Antibiotics as Anti-Inflammatory and Immunomodulatory Agents. 2005 ,	13
627	Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy. 2005 , 54, 1559-65	419
626	Mitochondrial inhibition and oxidative stress: reciprocating players in neurodegeneration. 2005 , 7, 1117-39	68
625	Selective up-regulation of caspase-3 gene expression following TCR engagement. 2005 , 42, 1345-54	19
624	Minocycline in phenotypic models of Huntington's disease. 2005 , 18, 206-17	50
623	Minocycline inhibits LPS-induced retinal microglia activation. 2005 , 47, 152-8	129
622	Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA. 2005 , 53, 241-9	150
621	In vivo studies on the protective role of minocycline against excitotoxicity caused by malonate or N-methyl-d-aspartate. 2005 , 191, 326-30	13
620	Minocycline delays disease onset and mortality in reovirus encephalitis. 2005 , 192, 331-9	40
619	Minocycline attenuates mechanical allodynia and proinflammatory cytokine expression in rat models of pain facilitation. 2005 , 115, 71-83	529
618	The physiology and pathophysiology of nitric oxide in the brain. 2005 , 76, 126-52	550
617	Apoptosis accompanied by up-regulation of TNF-alpha death pathway genes in the brain of Niemann-Pick type C disease. 2005 , 84, 9-17	79
616	Neuroprotective effect of zVAD against the neurotoxin 3-nitropropionic acid involves inhibition of calpain. 2005 , 49, 695-702	35
615	Minocycline prevents gentamicin-induced ototoxicity by inhibiting p38 MAP kinase phosphorylation and caspase 3 activation. 2005 , 131, 513-21	67
614	Involvement of mitochondrial potential and calcium buffering capacity in minocycline cytoprotective actions. 2005 , 133, 959-67	51
613	Effects of minocycline and tetracycline on retinal ganglion cell survival after axotomy. 2005 , 134, 575-82	50
612	Drosophila models of neurodegenerative disease. 2005 , 2, 438-46	83

611	The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies. 2005 , 2, 447-64	151
610	Dopamine and Glutamate in Psychiatric Disorders. 2005 ,	5
609	Bioinformatics Technologies. 2005 ,	10
608	Cystamine and cysteamine prevent 3-NP-induced mitochondrial depolarization of Huntington's disease knock-in striatal cells. 2006 , 23, 1701-10	54
607	Molecular pathogenesis of spinocerebellar ataxias. 2006 , 129, 1357-70	196
606	Minocycline and intracerebral hemorrhage: influence of injury severity and delay to treatment. 2006 , 197, 189-96	44
605	Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice. 2006 , 1762, 373-80	91
604	Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice. 2006 , 1762, 616-26	96
603	Protective role of Cop in Rip2/caspase-1/caspase-4-mediated HeLa cell death. 2006 , 1762, 742-54	11
602	rAAV-mediated shRNA ameliorated neuropathology in Huntington disease model mouse. 2006 , 343, 190-7	106
601	Effects of second generation tetracyclines on penicillin-epilepsy-induced hippocampal neuronal loss and motor incoordination in rats. 2006 , 79, 784-90	5
600	Brain-specific factors in combination with mutant huntingtin induce gene-specific transcriptional dysregulation. 2006 , 31, 661-75	11
599	Minocycline inhibits caspase-dependent and -independent cell death pathways and is neuroprotective against hippocampal damage after treatment with kainic acid in mice. 2006 , 398, 195-200	70
598	Tetracyclines: nonantibiotic properties and their clinical implications. 2006 , 54, 258-65	536
597	Protective effects of minocycline on behavioral changes and neurotoxicity in mice after administration of methamphetamine. 2006 , 30, 1381-93	117
596	Minocycline alleviates hypoxic-ischemic injury to developing oligodendrocytes in the neonatal rat brain. 2006 , 137, 425-35	121
595	Delayed minocycline treatment reduces long-term functional deficits and histological injury in a rodent model of focal ischemia. 2006 , 141, 27-33	64
594	Combined minocycline plus pyruvate treatment enhances effects of each agent to inhibit inflammation, oxidative damage, and neuronal loss in an excitotoxic animal model of Huntington's disease. 2006 , 141, 1835-48	62

593	The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseases. 2006 , 29, 518-27	289
592	Novel modulators of poly(ADP-ribose) polymerase. 2006 , 27, 626-30	61
591	Therapeutic Strategies in Huntington's Disease. 2006 , 2, 213-24	2
590	Huntington's Disease and Polyglutamine Expansion Neurodegenerative Diseases. 2006 , 95-111	1
589	Pharmaceutical, cellular and genetic therapies for Huntington's disease. 2006 , 110, 73-88	46
588	Early Phase Trials of Minocycline in Amyotrophic Lateral Sclerosis. 2006 , 1, 63-77	1
587	Multiple pathways contribute to the pathogenesis of Huntington disease. 2006 , 1, 19	77
586	Minocycline exerts inhibitory effects on multiple mitogen-activated protein kinases and IkappaBalpha degradation in a stimulus-specific manner in microglia. 2006 , 96, 314-23	148
585	Susceptibility to rotenone is increased in neurons from parkin null mice and is reduced by minocycline. 2006 , 97, 934-46	122
584	Minocycline neuroprotects, reduces microgliosis, and inhibits caspase protease expression early after spinal cord injury. 2006 , 97, 1314-26	182
583	The radical scavenger CR-6 protects SH-SY5Y neuroblastoma cells from oxidative stress-induced apoptosis: effect on survival pathways. 2006 , 98, 735-47	25
582	The age-related attenuation in long-term potentiation is associated with microglial activation. 2006 , 99, 1263-72	226
581	Huntingtin inhibits caspase-3 activation. 2006 , 25, 5896-906	73
580	Mouse models of triplet repeat diseases. 2006 , 32, 147-58	18
579	Nitric oxide-GAPDH-Siah: a novel cell death cascade. 2006 , 26, 527-38	138
578	Apoptotic cascades as possible targets for inhibiting cell death in Huntington's disease. 2006 , 253, 1137-42	30
577	Huntington's disease: from huntingtin function and dysfunction to therapeutic strategies. 2006 , 63, 2642-60	170
576	Protective effects of minocycline on 3,4-methylenedioxymethamphetamine-induced neurotoxicity in serotonergic and dopaminergic neurons of mouse brain. 2006 , 544, 1-9	55

575	Clinical implications of apoptosis in ischemic myocardium. 2006 , 31, 181-264	58
574	Minocycline treatment prevents cavitation in rats after a cortical devascularizing lesion. 2006 , 1090, 172-81	22
573	Behavioral and morphological effects of minocycline in the 6-hydroxydopamine rat model of Parkinson's disease. 2006 , 1093, 198-207	44
572	Aging and neurodegeneration. Molecular mechanisms of neuronal loss in Huntington's disease. 2006 , 127, 432-5	34
571	Modulation of sFas indicates apoptosis in human herpes simplex encephalitis. 2006 , 171, 171-6	16
570	Induction of apoptosis in cells expressing exogenous Hippi, a molecular partner of huntingtin-interacting protein Hip1. 2006 , 22, 242-56	29
569	A Drosophila ortholog of the human MRJ modulates polyglutamine toxicity and aggregation. 2006 , 24, 226-44	35
568	Caspase-dependent and -independent cell death induced by 3-nitropropionic acid in rat cortical neurons. 2006 , 98, 93-101	21
567	Inhibitory effect of minocycline on amyloid beta fibril formation and human microglial activation. 2006 , 53, 233-40	67
566	Minocycline delays death of retinal ganglion cells in experimental glaucoma and after optic nerve transection. 2006 , 124, 520-6	77
565	From mice to macaques--animal models of HIV nervous system disease. 2006 , 4, 293-305	43
564	Pharmacological management of Huntington's disease: an evidence-based review. 2006 , 12, 2701-20	133
563	Therapeutic approaches to polyglutamine diseases: combating protein misfolding and aggregation. 2006 , 12, 2543-55	33
562	A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. 2006 , 66, 664-71	353
561	Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model. 2006 , 20, 234-9	120
560	A requirement for microglial TLR4 in leukocyte recruitment into brain in response to lipopolysaccharide. 2006 , 177, 8103-10	114
559	Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations. 2006 , 103, 9685-90	204
558	Regulation of inducible nitric oxide synthase gene in glial cells. 2006 , 8, 929-47	255

557	Cloning and functional characterization of the murine caspase-3 gene promoter. 2006 , 25, 104-15	6
556	Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease. 2006 , 103, 9345-50	85
555	Minocycline alleviates death of oligodendrocytes by inhibiting pro-nerve growth factor production in microglia after spinal cord injury. 2007 , 27, 7751-61	209
554	Nitric oxide and peroxynitrite in health and disease. 2007 , 87, 315-424	4407
553	Established and emerging therapies for Huntington's disease. 2007 , 7, 579-87	12
552	Minocycline attenuates neuronal cell death and improves cognitive impairment in Alzheimer's disease models. 2007 , 32, 2393-404	219
551	Microglial activation and its implications in the brain diseases. 2007 , 14, 1189-97	689
550	Inflammatory caspases: targets for novel therapies. 2007 , 13, 367-85	75
549	Inhibition of caspase-1/interleukin-1beta signaling prevents degeneration of retinal capillaries in diabetes and galactosemia. 2007 , 56, 224-30	219
548	Minocycline down-regulates MHC II expression in microglia and macrophages through inhibition of IRF-1 and protein kinase C (PKC)alpha/betall. 2007 , 282, 15208-16	113
547	Inflammatory Caspases: Targets for Novel Therapies. 2007 , 13, 365-383	10
546	Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. 2007 , 2007, 95103	448
545	Interleukin-1beta and caspase-1: players in the regulation of age-related cognitive dysfunction. 2007 , 18, 137-48	77
544	Evolving therapies for multiple sclerosis. 2007 , 79, 571-88	2
543	Microglial activation in presymptomatic Huntington's disease gene carriers. 2007 , 130, 1759-66	324
542	A systematic review of the treatment studies in Huntington's disease since 1990. 2007 , 8, 141-53	64
541	Huntington's disease: progress and potential in the field. 2007 , 16, 1933-53	32
540	Pneumococcal cell wall-induced meningitis impairs adult hippocampal neurogenesis. 2007 , 75, 4289-97	22

539	Autosomal dominant primary lateral sclerosis. 2007 , 68, 1156-7	20
538	Minocycline attenuates hyperlocomotion and prepulse inhibition deficits in mice after administration of the NMDA receptor antagonist dizocilpine. 2007 , 32, 2004-10	92
537	Polyglutamine diseases: emerging concepts in pathogenesis and therapy. 2007 , 16 Spec No. 2, R115-23	204
536	Tetracycline delays ocular motility decline in chronic progressive external ophthalmoplegia. 2007 , 68, 1159-60	6
535	Minocycline blocks acute bilirubin-induced neurological dysfunction in jaundiced Gunn rats. 2007 , 92, 219-26	34
534	Developing a neuroprotective therapy for Parkinson's and Huntington's diseases. 2007 , 17, 159-172	1
533	Chronic Intrathecal Infusion of Minocycline Prevents the Development of Spinal-Nerve Ligation-Induced Pain in Rats. 2007 , 32, 209-216	
532	Possible antipsychotic effects of minocycline in patients with schizophrenia. 2007 , 31, 304-7	83
531	The role of poly(ADP-ribose) polymerase-1 in CNS disease. 2007 , 145, 1267-72	124
530	Transient neuroprotection by minocycline following traumatic brain injury is associated with attenuated microglial activation but no changes in cell apoptosis or neutrophil infiltration. 2007 , 204, 220-33	195
529	Differential neuroprotective effects of a minocycline-based drug cocktail in transient and permanent focal cerebral ischemia. 2007 , 204, 433-42	56
528	Imaging microglial activation in Huntington's disease. 2007 , 72, 148-51	103
527	The mitochondrial permeability transition in neurologic disease. 2007 , 50, 983-97	126
526	Time-related changes in constitutive and inducible nitric oxide synthases in the rat striatum in a model of Huntington's disease. 2007 , 28, 1200-7	36
525	Minocycline modulates neuroinflammation independently of its antimicrobial activity in staphylococcus aureus-induced brain abscess. 2007 , 171, 1199-214	62
524	Parkinson's Disease. 2007 ,	1
523	Improved sleep and neurocognitive functions in a child with thalamic lesions on sodium oxybate. 2007 , 68, 1157-8	8
522	Systemic infections in multiple sclerosis and experimental autoimmune encephalomyelitis. 2007 , 113, 124-30	18

521	Minocycline treatment in acute stroke: an open-label, evaluator-blinded study. 2007 , 69, 1404-10	357
520	Anti-inflammatory activity of tetracyclines. 2007 , 25, 133-5, v	79
519	Chronic intrathecal infusion of minocycline prevents the development of spinal-nerve ligation-induced pain in rats. 2007 , 32, 209-16	42
518	Protective effects of minocycline on the reduction of dopamine transporters in the striatum after administration of methamphetamine: a positron emission tomography study in conscious monkeys. 2007 , 61, 577-81	54
517	Involvement of interferon-gamma in microglial-mediated loss of dopaminergic neurons. 2007 , 27, 3328-37	223
516	Microglial activation mediates neurodegeneration related to oligodendroglial alpha-synucleinopathy: implications for multiple system atrophy. 2007 , 22, 2196-203	179
515	Minocycline modulates chemokine receptors but not interleukin-10 mRNA expression in hypoxic-ischemic neonatal rat brain. 2007 , 85, 2450-9	32
514	Polyglutamine-mediated neurodegeneration: use of chaperones as prevention strategy. 2007 , 72, 359-66	11
513	Selective inhibitors of death in mutant huntingtin cells. 2007 , 3, 99-100	35
512	Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. <i>Nature Medicine</i> , 2007 , 13, 1349-58	50.5 314
511	Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease. 2007 , 10, 1355-60	358
510	Nortriptyline delays disease onset in models of chronic neurodegeneration. 2007 , 26, 633-41	42
509	Neuroprotectant minocycline depresses glutamatergic neurotransmission and Ca(2+) signalling in hippocampal neurons. 2007 , 26, 2481-95	81
508	Effect of minocycline on inflammation-induced damage to the blood-brain barrier and white matter during development. 2007 , 26, 3465-74	29
507	Minocycline and riluzole brain disposition: interactions with p-glycoprotein at the blood-brain barrier. 2007 , 103, 164-73	53
506	Cysteinyl leukotriene receptor 1 partially mediates brain cryoinjury in mice. 2007 , 28, 945-52	19
505	Effect of synthetic matrix metalloproteinase inhibitors on lipopolysaccharide-induced blood-brain barrier opening in rodents: Differences in response based on strains and solvents. 2007 , 1133, 186-92	52
504	Minocycline, a second-generation tetracycline, as a neuroprotective agent in an animal model of schizophrenia. 2007 , 1154, 154-62	65

503	Re-evaluation of mitochondrial permeability transition as a primary neuroprotective target of minocycline. 2007 , 25, 198-205	40
502	Doxycycline inhibits MMPs via modulation of plasminogen activators in focal cerebral ischemia. 2007 , 25, 506-13	38
501	Multiple neuroprotective mechanisms of minocycline in autoimmune CNS inflammation. 2007 , 25, 514-25	92
500	Inhibition of p38 mitogen activated protein kinase activation and mutant SOD1(G93A)-induced motor neuron death. 2007 , 26, 332-41	91
499	Soluble expanded PABPN1 promotes cell death in oculopharyngeal muscular dystrophy. 2007 , 26, 546-57	35
498	Lack of minocycline efficiency in genetic models of Huntington's disease. 2007 , 9, 47-54	22
497	Neuroprotection against neurodegenerative diseases. 2007 , 35, 55-84	23
496	The neurotoxic effect of cuprizone on oligodendrocytes depends on the presence of pro-inflammatory cytokines secreted by microglia. 2007 , 32, 279-92	122
495	Increased caspase-2, calpain activations and decreased mitochondrial complex II activity in cells expressing exogenous huntingtin exon 1 containing CAG repeat in the pathogenic range. 2007 , 27, 1127-45	29
494	The involvement of matrix metalloproteinases 2 and 9 in rat retinal ischemia. 2007 , 245, 725-32	25
493	Improvement by minocycline of methamphetamine-induced impairment of recognition memory in mice. 2008 , 196, 233-41	73
492	Spinocerebellar ataxias caused by polyglutamine expansions: a review of therapeutic strategies. 2008 , 7, 215-21	39
491	The anti-fibrillogenic activity of tetracyclines on PrP 106-126: a 3D-QSAR study. 2008 , 14, 987-94	19
490	Minocycline reduces engraftment and activation of bone marrow-derived cells but sustains their phagocytic activity in a mouse model of Alzheimer's disease. 2008 , 56, 1767-79	40
489	Neuroprotection for Huntington's disease: ready, set, slow. 2008 , 5, 226-36	37
488	The accelerated simian immunodeficiency virus macaque model of human immunodeficiency virus-associated neurological disease: from mechanism to treatment. 2008 , 14, 309-17	67
487	Sp1-like sequences mediate human caspase-3 promoter activation by p73 and cisplatin. 2008 , 275, 2200-13	18
486	Molecular chaperones as regulators of cell death. 2008 , 27, 6489-506	36

485	Novel therapeutic strategies for multiple sclerosis--a multifaceted adversary. 2008 , 7, 909-25	130
484	Delayed combinatorial treatment with flavopiridol and minocycline provides longer term protection for neuronal soma but not dendrites following global ischemia. 2008 , 105, 703-13	20
483	Minocycline neuroprotects, reduces microglial activation, inhibits caspase 3 induction, and viral replication following Japanese encephalitis. 2008 , 105, 1582-95	128
482	A re-assessment of minocycline as a neuroprotective agent in a rat spinal cord contusion model. 2008 , 1243, 146-51	71
481	Minocycline prevents the development of neuropathic pain, but not acute pain: possible anti-inflammatory and antioxidant mechanisms. 2008 , 601, 79-87	102
480	Drug-induced arthritic and connective tissue disorders. 2008 , 38, 249-64	21
479	Therapeutics for neonatal brain injury. 2008 , 120, 43-53	72
478	Unexpected off-targeting effects of anti-huntingtin ribozymes and siRNA in vivo. 2008 , 29, 446-55	19
477	Neurodegenerative Diseases. 2008 , 565-588	0
476	Inhibitors of cytochrome c release with therapeutic potential for Huntington's disease. 2008 , 28, 9473-85	86
475	NF- κ B/NOS cross-talk induced by mitochondrial complex II inhibition: implications for Huntington's disease. 2008 , 434, 241-6	34
474	Limited minocycline neuroprotection after balloon-compression spinal cord injury in the rat. 2008 , 433, 246-9	33
473	Neuroprotective role of minocycline in co-cultures of human fetal neurons and microglia. 2008 , 211, 41-51	38
472	Combined treatment with atorvastatin and minocycline suppresses severity of EAE. 2008 , 211, 214-26	45
471	A novel role of minocycline: attenuating morphine antinociceptive tolerance by inhibition of p38 MAPK in the activated spinal microglia. 2008 , 22, 114-23	163
470	Role of extracellular factors in axon regeneration in the CNS: implications for therapy. 2008 , 3, 907-23	41
469	Amyotrophic lateral sclerosis: from current developments in the laboratory to clinical implications. 2008 , 10, 405-43	115
468	Cytoplasmic inclusions of Htt exon1 containing an expanded polyglutamine tract suppress execution of apoptosis in sympathetic neurons. 2008 , 28, 14401-15	17

467	Phosphorylation of profilin by ROCK1 regulates polyglutamine aggregation. 2008 , 28, 5196-208	125
466	Therapeutic approach in Huntington's disease. 2008 , 89, 631-8	
465	Huntington Disease. 2008 , 207-266	4
464	Neurodegeneration and neuroprotective agents in multiple sclerosis. 2008 , 3, 153-65	6
463	Chronic inflammatory pain and the neurovascular unit: a central role for glia in maintaining BBB integrity?. 2008 , 14, 1625-43	52
462	Delayed treatment with minocycline ameliorates neurologic impairment through activated microglia expressing a high-mobility group box1-inhibiting mechanism. 2008 , 39, 951-8	119
461	Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. 2009 , 46, 94-102	341
460	Huntington's Disease. 2008 , 293-315	
459	A critical evaluation of adenosine A2A receptors as potentially "druggable" targets in Huntington's disease. 2008 , 14, 1500-11	58
458	High throughput screening for neurodegeneration and complex disease phenotypes. 2008 , 11, 238-48	23
457	Minocycline as adjunctive therapy for schizophrenia: an open-label study. 2008 , 31, 287-92	112
456	Immunomodulatory Properties of Antibiotics. 2008 , 1, 68-79	86
455	Brain and plasma riluzole pharmacokinetics: effect of minocycline combination. 2009 , 12, 209-17	28
454	Tetracyclines and prion infectivity. 2009 , 9, 23-30	39
453	Rapid Determination of Minocycline in Pharmaceutical Formulations and Human Urine/Serum Samples Based on the Minocycline-Europium-Sodium Dodecylbenzene Sulfonate Luminescence System. 2009 , 42, 228-242	6
452	Minocycline in the treatment of patients with primary sclerosing cholangitis: results of a pilot study. 2009 , 104, 83-8	90
451	The antibiotics doxycycline and minocycline inhibit the inflammatory responses to the Lyme disease spirochete <i>Borrelia burgdorferi</i> . 2009 , 199, 1379-88	56
450	Apoptosis and human diseases: mitochondrion damage and lethal role of released cytochrome C as proapoptotic protein. 2009 , 16, 4058-65	162

449	Minocycline as a potential therapeutic agent in neurodegenerative disorders characterised by protein misfolding. 2009 , 3, 78-83	55
448	Role for Toll-like receptor 2 in the immune response to Streptococcus pneumoniae infection in mouse otitis media. 2009 , 77, 3100-8	34
447	High-throughput screening identifies two classes of antibiotics as radioprotectors: tetracyclines and fluoroquinolones. 2009 , 15, 7238-45	50
446	Minocycline restores striatal tyrosine hydroxylase in GDNF heterozygous mice but not in methamphetamine-treated mice. 2009 , 33, 459-66	21
445	Y-27632 improves rotarod performance and reduces huntingtin levels in R6/2 mice. 2009 , 36, 413-20	55
444	Minocycline attenuates experimental colitis in mice by blocking expression of inducible nitric oxide synthase and matrix metalloproteinases. 2009 , 237, 69-82	52
443	Therapeutic targets and limits of minocycline neuroprotection in experimental ischemic stroke. 2009 , 10, 126	108
442	Inhibitory modulation of the mitochondrial permeability transition by minocycline. 2009 , 77, 888-96	44
441	Attenuation of oxidative stress, inflammation and apoptosis by minocycline prevents retrovirus-induced neurodegeneration in mice. 2009 , 1286, 174-84	34
440	Effects of treatments on inflammatory and apoptotic markers in the CNS of mice with globoid cell leukodystrophy. 2009 , 1300, 146-58	55
439	The R6 lines of transgenic mice: a model for screening new therapies for Huntington's disease. 2009 , 59, 410-31	56
438	Intracerebral transplantation of neural stem cells combined with trehalose ingestion alleviates pathology in a mouse model of Huntington's disease. 2009 , 87, 26-33	39
437	Minocycline: a neuroprotective agent for hypoxic-ischemic brain injury in the neonate?. 2009 , 87, 599-608	58
436	Design of pH-independent extended release matrix tablets of minocycline hydrochloride for the treatment of dementia. 2009 , 32, 1593-8	4
435	Dual modulation of ERK1/2 and p38 MAP kinase activities induced by minocycline reverses the neurotoxic effects of the prion protein fragment 90-231. 2009 , 15, 138-54	29
434	Impairment of mitochondrial function by minocycline. 2009 , 276, 1729-38	31
433	The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies. 2009 , 110, 1737-65	154
432	Minocycline reduces the development of abnormal tau species in models of Alzheimer's disease. 2009 , 23, 739-50	98

431	Bone-marrow-derived mesenchymal stem cell therapy for neurodegenerative diseases. 2009 , 9, 1487-97	88
430	Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. 2009 , 132, 3152-64	275
429	Hydrogen peroxide-induced Akt phosphorylation regulates Bax activation. 2009 , 91, 577-85	62
428	Minocycline and neurodegenerative diseases. 2009 , 196, 168-79	338
427	Minocycline attenuates 5-fluorouracil-induced small intestinal mucositis in mouse model. 2009 , 389, 634-9	45
426	The influence of microglia on the pathogenesis of Parkinson's disease. 2009 , 89, 277-87	213
425	Antioxidant potential of Minocycline in Japanese Encephalitis Virus infection in murine neuroblastoma cells: correlation with membrane fluidity and cell death. 2009 , 54, 464-70	61
424	Heterogeneity of microglia and TNF signaling as determinants for neuronal death or survival. 2009 , 30, 785-93	72
423	Emerging drug therapies in Huntington's disease. 2009 , 14, 273-97	23
422	Turnover of newborn olfactory bulb neurons optimizes olfaction. 2009 , 29, 12302-14	112
421	Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. 2009 , 187, 761-72	777
420	The antiapoptotic activity of melatonin in neurodegenerative diseases. 2009 , 15, 345-57	176
419	Neuroprotection in the newborn infant. 2009 , 36, 859-80, vii	57
418	Distinct neuroinflammatory profile in post-mortem human Huntington's disease. 2009 , 20, 1098-103	128
417	Spinal microglial expression and mechanical hypersensitivity in a postoperative pain model: comparison with a neuropathic pain model. 2009 , 111, 640-8	42
416	Anti-Inflammatory Agents in Parkinsons Disease. 2009 , 8, 72-84	
415	A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. 2010 , 71, 138-49	298
414	Neuroinflammation in Huntington's disease. 2010 , 117, 1001-8	133

413	Cellular and molecular pathways triggering neurodegeneration in the spinocerebellar ataxias. 2010 , 9, 148-66	73
412	A study on the mechanisms by which minocycline protects against MDMA ('ecstasy')-induced neurotoxicity of 5-HT cortical neurons. 2010 , 18, 187-99	33
411	HIV-associated neurocognitive disorder: pathogenesis and therapeutic opportunities. 2010 , 5, 294-309	171
410	Modifiers and mechanisms of multi-system polyglutamine neurodegenerative disorders: lessons from fly models. 2010 , 89, 497-526	17
409	Pharmacologic Protocols for Spinal Cord-Injured Athletes. 2010 , 22, 181-192	1
408	Therapeutic Prospects for Polyglutamine Disease. 2010 , 887-902	1
407	A futility study of minocycline in Huntington's disease. 2010 , 25, 2219-24	67
406	Identification and evaluation of small molecule pan-caspase inhibitors in Huntington's disease models. 2010 , 17, 1189-200	45
405	Adaptive immune regulation of glial homeostasis as an immunization strategy for neurodegenerative diseases. 2010 , 114, 1261-76	32
404	Inhibitors of protein disulfide isomerase suppress apoptosis induced by misfolded proteins. 2010 , 6, 900-6	227
403	Anti-inflammatory impact of minocycline in a mouse model of tauopathy. 2010 , 1, 136	70
402	Chemotactic and cytotoxic effects of minocycline on human retinal pigment epithelial cells. 2010 , 51, 2721-9	15
401	Comprehensive behavioral testing in the R6/2 mouse model of Huntington's disease shows no benefit from CoQ10 or minocycline. 2010 , 5, e9793	51
400	Etiology, Pathology, and Pathogenesis. 2010 , 417-431	
399	Minocycline is cytoprotective in human trabecular meshwork cells and optic nerve head astrocytes by increasing expression of XIAP, survivin, and Bcl-2. 2010 , 4, 591-604	24
398	Reductions in amyloid-beta-derived neuroinflammation, with minocycline, restore cognition but do not significantly affect tau hyperphosphorylation. 2010 , 21, 527-42	67
397	Minocycline is cytoprotective in human corneal endothelial cells and induces anti-apoptotic B-cell CLL/lymphoma 2 (Bcl-2) and X-linked inhibitor of apoptosis (XIAP). 2010 , 94, 940-6	12
396	Differential activation of mitochondrial apoptotic pathways by vasculotropic amyloid-beta variants in cells composing the cerebral vessel walls. 2010 , 24, 229-41	57

395	Minocycline prevents osmotic demyelination syndrome by inhibiting the activation of microglia. 2010 , 21, 2090-8	41
394	Doxycycline inhibits proinflammatory cytokines but not acute cerebral cytogenesis after hypoxia-ischemia in neonatal rats. 2010 , 35, 20-32	36
393	Prospects for minocycline neuroprotection. 2010 , 67, 1442-8	198
392	Minocycline to improve neurologic outcome in stroke (MINOS): a dose-finding study. 2010 , 41, 2283-7	181
391	Neurobiology of injury to the developing brain. 2010 , 6, 328-36	102
390	Minocycline protects against neurologic complications of rapid correction of hyponatremia. 2010 , 21, 2099-108	23
389	Effect of an antimicrobial agent on atherosclerotic plaques: assessment of metalloproteinase activity by molecular imaging. 2010 , 55, 1240-1249	28
388	Minocycline inhibits glial proliferation in the H-Tx rat model of congenital hydrocephalus. 2010 , 7, 7	32
387	Systemic administration of 3-nitropropionic acid points out a different role for active caspase-3 in neurons and astrocytes. 2010 , 56, 443-50	18
386	Molecular mechanisms and potential therapeutical targets in Huntington's disease. 2010 , 90, 905-81	616
385	Clinical Features and Care. 2010 , 432-456	1
384	Heat shock proteins: therapeutic drug targets for chronic neurodegeneration?. 2010 , 11, 198-215	23
383	Bacterial and human peptidylarginine deiminases: targets for inhibiting the autoimmune response in rheumatoid arthritis?. 2010 , 12, 209	72
382	Neurochemical Aspects of Neurotraumatic and Neurodegenerative Diseases. 2010 ,	74
381	Blockade of acute microglial activation by minocycline promotes neuroprotection and reduces locomotor hyperactivity after closed head injury in mice: a twelve-week follow-up study. 2010 , 27, 911-21	125
380	Tetracyclines: a pleiotropic family of compounds with promising therapeutic properties. Review of the literature. 2010 , 299, C539-48	286
379	Minocycline reduces prostaglandin E synthase expression and 8-isoprostane formation in LPS-activated primary rat microglia. 2011 , 33, 576-80	16
378	Analysis of a second-generation tetracycline antibiotic minocycline in human plasma by LC-MS/MS. 2011 , 3, 2177-94	7

377	Experimental models of HD and reflection on therapeutic strategies. 2011 , 98, 419-81	14
376	The yin and yang of microglia. 2011 , 33, 199-209	232
375	Tetracycline compounds with non-antimicrobial organ protective properties: possible mechanisms of action. 2011 , 63, 102-7	123
374	The intestinal anti-inflammatory effect of minocycline in experimental colitis involves both its immunomodulatory and antimicrobial properties. 2011 , 63, 308-19	45
373	Attenuation of microglial and IL-1 signaling protects mice from acute alcohol-induced sedation and/or motor impairment. 2011 , 25 Suppl 1, S155-64	63
372	Minocycline reduces glioma expansion and invasion by attenuating microglial MT1-MMP expression. 2011 , 25, 624-8	71
371	Huntington's disease: can mice lead the way to treatment?. 2011 , 69, 423-35	173
370	Caspase-6 and neurodegeneration. 2011 , 34, 646-56	102
369	Treatment with minocycline after disease onset alters astrocyte reactivity and increases microgliosis in SOD1 mutant mice. 2011 , 228, 69-79	70
368	Huntington's disease is a TH17 related autoimmune disorder against mutant Huntingtin coded by multiple CAG triplets. 2011 ,	0
367	Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease. 2011 , 6, e16172	109
366	Caspase-3 contributes to ZO-1 and Cl-5 tight-junction disruption in rapid anoxic neurovascular unit damage. 2011 , 6, e16760	61
365	Matter of life and death: the pharmacological approaches targeting apoptosis in brain diseases. 2011 , 17, 215-29	53
364	Medical management of Parkinson's disease: focus on neuroprotection. 2011 , 9, 350-9	28
363	Autophagy, inflammation and neurodegenerative disease. 2011 , 33, 197-204	65
362	The role of immunity in Huntington's disease. 2011 , 16, 889-902	48
361	Doxycycline protects against pilocarpine-induced convulsions in rats, through its antioxidant effect and modulation of brain amino acids. 2011 , 98, 525-32	21
360	Pharmacological interventions for spinal cord injury: where do we stand? How might we step forward?. 2011 , 132, 15-29	67

359	Minocycline fails to modulate cerebrospinal fluid HIV infection or immune activation in chronic untreated HIV-1 infection: results of a pilot study. 2011 , 8, 17	13
358	Neuroprotective mechanisms of minocycline against sphingomyelinase/ceramide toxicity: Roles of Bcl-2 and thioredoxin. 2011 , 50, 710-21	13
357	Attenuation of proinflammatory cytokines and apoptotic process by verapamil and diltiazem against quinolinic acid induced Huntington like alterations in rats. 2011 , 1372, 115-26	29
356	Testing the therapeutic potential of doxycycline in a <i>Drosophila melanogaster</i> model of Alzheimer disease. 2011 , 286, 41647-41655	54
355	Anti-inflammatory properties of doxycycline and minocycline in experimental models: an in vivo and in vitro comparative study. 2011 , 19, 99-110	75
354	Reduced PBR/TSPO expression after minocycline treatment in a rat model of focal cerebral ischemia: a PET study using [(18)F]DPA-714. 2011 , 13, 10-5	57
353	Similarities and differences between primary and secondary degeneration of the optic nerve and the effect of minocycline. 2011 , 249, 849-57	25
352	Genotype-, aging-dependent abnormal caspase activity in Huntington disease blood cells. 2011 , 118, 1599-607	14
351	Minocycline development for acute ischemic stroke. 2011 , 2, 202-8	77
350	Neuroinflammation is associated with changes in glial mGluR5 expression and the development of neonatal excitotoxic lesions. 2011 , 59, 188-99	55
349	The inflammation hypothesis in geriatric depression. 2011 , 26, 1109-18	123
348	Cell-based treatments for huntington's disease. 2011 , 98, 483-508	13
347	Amyotrophic lateral sclerosis: from research to therapeutic attempts and therapeutic perspectives. 2011 , 18, 5655-65	34
346	Neues zu neurologischen Bewegungsstörungen 2011. 2011 , 38, 222-233	
345	The role of minocycline in ischemia-reperfusion injury: a comprehensive review of an old drug with new implications. 2011 , 6, 123-32	13
344	Combining drug and gene similarity measures for drug-target elucidation. 2011 , 18, 133-45	120
343	Neural circuit architecture defects in a <i>Drosophila</i> model of Fragile X syndrome are alleviated by minocycline treatment and genetic removal of matrix metalloproteinase. 2011 , 4, 673-85	75
342	Minocycline inhibits cell death and decreases mutant Huntingtin aggregation by targeting Apaf-1. 2011 , 20, 3545-53	25

341	Minocycline suppresses activation of nuclear factor of activated T cells 1 (NFAT1) in human CD4+ T cells. 2011 , 286, 11275-82	34
340	Minocycline inhibits the growth of glioma by inducing autophagy. 2011 , 7, 166-75	64
339	Inflammatory Animal Model for Parkinson's Disease: The Intranigral Injection of LPS Induced the Inflammatory Process along with the Selective Degeneration of Nigrostriatal Dopaminergic Neurons. 2011 , 2011, 476158	32
338	Huntington disease. 2011 , 311-334	0
337	Neuroprotection by minocycline caused by direct and specific scavenging of peroxynitrite. 2011 , 286, 4991-5002	74
336	The melatonin MT1 receptor axis modulates mutant Huntingtin-mediated toxicity. 2011 , 31, 14496-507	113
335	Minocycline treatment for HIV-associated cognitive impairment: results from a randomized trial. 2011 , 77, 1135-42	66
334	Efficacy of minocycline in acute ischemic stroke: a single-blinded, placebo-controlled trial. 2012 , 60, 23-8	76
333	Huntington's disease. 2012 , 106, 507-26	10
332	Classification Framework and Chemical Biology of Tetracycline-Structure-Based Drugs. 2012 , 1, 1-13	47
331	Anti-apoptotic and anti-oxidative mechanisms of minocycline against sphingomyelinase/ceramide neurotoxicity: implication in Alzheimer's disease and cerebral ischemia. 2012 , 46, 940-50	43
330	Tetracyclines: drugs with huge therapeutic potential. 2012 , 12, 44-52	98
329	Inflammatory cytokines, growth factors, and depression. 2012 , 18, 5920-35	38
328	Translational potential of preclinical trials of neuroprotection through pharmacotherapy for spinal cord injury. 2012 , 17, 157-229	53
327	A new mouse mutant of the Cdh23 gene with early-onset hearing loss facilitates evaluation of otoprotection drugs. 2012 , 12, 30-44	32
326	Acute minocycline treatment mitigates the symptoms of mild blast-induced traumatic brain injury. 2012 , 3, 111	109
325	Differential detection and distribution of microglial and hematogenous macrophage populations in the injured spinal cord of lys-EGFP-ki transgenic mice. 2012 , 71, 180-97	50
324	Machado-Joseph disease and other rare spinocerebellar ataxias. 2012 , 724, 172-88	15

323	Minocycline cannot protect neurons against bilirubin-induced hyperexcitation in the ventral cochlear nucleus. 2012 , 237, 96-102	7
322	Redox regulation of protein misfolding, mitochondrial dysfunction, synaptic damage, and cell death in neurodegenerative diseases. 2012 , 238, 12-21	84
321	Huntingtin aggregation kinetics and their pathological role in a Drosophila Huntington's disease model. 2012 , 190, 581-600	55
320	Longitudinal analysis of gene expression and behaviour in the HdhQ150 mouse model of Huntington's disease. 2012 , 88, 199-209	17
319	Suppression of aggregate formation of mutant huntingtin potentiates CREB-binding protein sequestration and apoptotic cell death. 2012 , 49, 127-37	16
318	Effects of minocycline on endogenous neural stem cells after experimental stroke. 2012 , 215, 174-83	37
317	Prevention of hypoglycemia-induced neuronal death by minocycline. 2012 , 9, 225	25
316	Pathological features in the LmnaDhe/+ mutant mouse provide a novel model of human otitis media and laminopathies. 2012 , 181, 761-74	16
315	Hyperbranched polydiselenide as a self assembling broad spectrum anticancer agent. 2012 , 33, 7765-74	92
314	Targeting mutant huntingtin for the development of disease-modifying therapy. 2012 , 17, 1217-23	14
313	Therapeutic approaches to preventing cell death in Huntington disease. 2012 , 99, 262-80	20
312	Huntington disease and the huntingtin protein. 2012 , 107, 189-214	71
311	Mouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II. 2012 , 46, 430-66	33
310	Minocycline: therapeutic potential in psychiatry. 2012 , 26, 391-401	91
309	Minocycline down-regulates topical mucosal inflammation during the application of microbicide candidates. 2012 , 7, e43211	6
308	The Protective Effect of Minocycline in a Paraquat-Induced Parkinson's Disease Model in Drosophila is Modified in Altered Genetic Backgrounds. 2012 , 2012, 938528	26
307	Genetic Deficiency of Complement Component 3 Does Not Alter Disease Progression in a Mouse Model of Huntington's Disease. 2012 , 1, 107-18	18
306	Mesenchymal Stem Cells in CNS Regeneration. 2012 ,	

305	Central Nervous System Injury and Neuroprotection. 2012 , 869-891	
304	Fragile X syndrome and targeted treatment trials. 2012 , 54, 297-335	77
303	Targeting neuro-inflammatory cytokines and oxidative stress by minocycline attenuates quinolinic-acid-induced Huntington's disease-like symptoms in rats. 2012 , 22, 310-20	42
302	Tetracyclines and pain. 2012 , 385, 225-41	29
301	Antibiotics acting as neuroprotectants via mechanisms independent of their anti-infective activities. 2013 , 73, 174-82	11
300	Impact of minocycline on neurodegenerative diseases in rodents: a meta-analysis. 2013 , 24, 553-62	32
299	Multiple Sclerosis Immunology. 2013 ,	4
298	Minocycline prevents retinal inflammation and vascular permeability following ischemia-reperfusion injury. 2013 , 10, 149	87
297	Minocycline: far beyond an antibiotic. 2013 , 169, 337-52	513
296	Prevention and reversal of ketamine-induced schizophrenia related behavior by minocycline in mice: Possible involvement of antioxidant and nitrenergic pathways. 2013 , 27, 1032-43	81
295	Nanoliposomal minocycline for ocular drug delivery. 2013 , 9, 130-40	39
294	Minocycline modulates neuroprotective effect of hesperidin against quinolinic acid induced Huntington's disease like symptoms in rats: behavioral, biochemical, cellular and histological evidences. 2013 , 720, 16-28	39
293	Minocycline exerts acute inhibitory effects on cerebral cortex excitability in humans. 2013 , 107, 302-5	8
292	Doxycycline restrains glia and confers neuroprotection in a 6-OHDA Parkinson model. 2013 , 61, 1084-100	64
291	Protein truncation as a common denominator of human neurodegenerative foldopathies. 2013 , 48, 516-32	12
290	Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. 2013 , 246, 199-229	601
289	A new face for old antibiotics: tetracyclines in treatment of amyloidoses. 2013 , 56, 5987-6006	63
288	What is behind the non-antibiotic properties of minocycline?. 2013 , 67, 18-30	97

287	Korean Red Ginseng Extract Attenuates 3-Nitropropionic Acid-Induced Huntington's-Like Symptoms. 2013 , 2013, 237207	27
286	Fragile X Clinical Features and Neurobiology. 2013 , 631-650	
285	Surveying the landscape of Huntington's disease mechanisms, measurements, and medicines. 2013 , 2, 405-36	7
284	Characterization of neuronal cell death in the spiral ganglia of a mouse model of endolymphatic hydrops. 2013 , 34, 559-69	13
283	Minocycline mediated mitochondrial cytoprotection: premises for therapy of cerebrovascular and neurodegenerative diseases. 2013 , 14, 47-55	14
282	On the mechanism of action of antipsychotic drugs: a chemical reaction not receptor blockade. 2013 , 10, 195-208	5
281	Biotic acts of antibiotics. 2013 , 4, 241	28
280	Accelerated aging during chronic oxidative stress: a role for PARP-1. 2013 , 2013, 680414	25
279	AAV-dominant negative tumor necrosis factor (DN-TNF) gene transfer to the striatum does not rescue medium spiny neurons in the YAC128 mouse model of Huntington's disease. 2014 , 9, e96544	6
278	Profile of minocycline and its potential in the treatment of schizophrenia. 2014 , 10, 1103-11	30
277	Minocycline decreases blood glucose and triglyceride levels and reverses histological and immunohisto-chemical alterations in pancreas, liver and kidney of alloxan-induced diabetic rats. 2014 , 5, 29-40	2
276	. 2014 ,	2
275	Investigational drugs for the management of Huntington's disease: are we there yet?. 2014 , 23, 1595-603	3
274	From pathways to targets: understanding the mechanisms behind polyglutamine disease. 2014 , 2014, 701758	43
273	Inhibition of soluble tumor necrosis factor is therapeutic in Huntington's disease. 2014 , 23, 4328-44	69
272	Inflammation as a target of minocycline: special interest in the regulation of inflammasome signaling. 2014 , 1,	4
271	THE NEUROPROTECTIVE EFFECTS ON RETINAL STRUCTURE BY MINOCYCLINE IN A RAT MODEL OF HIGH IOP INDUCED RETINAL ISCHEMIA INJURY. 2014 , 40, 83-87	
270	Minocycline attenuates HIV-1 infection and suppresses chronic immune activation in humanized NOD/LtsZ-scidIL-2R(hull) mice. 2014 , 142, 562-72	16

269	Inhibition of prothrombin kringle-2-induced inflammation by minocycline protects dopaminergic neurons in the substantia nigra in vivo. 2014 , 25, 489-95	12
268	Antioxidants: potential antiviral agents for Japanese encephalitis virus infection. 2014 , 24, 30-6	38
267	Minocycline upregulates pro-survival genes and downregulates pro-apoptotic genes in experimental glaucoma. 2014 , 252, 761-72	27
266	TRAIL-induced programmed necrosis as a novel approach to eliminate tumor cells. 2014 , 14, 74	44
265	Paradoxical effects of minocycline in the developing mouse somatosensory cortex. 2014 , 62, 399-410	32
264	From Catalysis to Mass Action: The Evolution of CHDI Foundation, a Drug-Development Organization Devoted to Huntington's Disease. 2014 , 411-435	
263	Effects of glycerol on apoptotic signaling pathways during boar spermatozoa cryopreservation. 2014 , 68, 395-404	25
262	Inactivation of Apaf1 reduces the formation of mutant huntingtin-dependent aggregates and cell death. 2014 , 262, 83-91	3
261	A mitochondrial basis for Huntington's disease: therapeutic prospects. 2014 , 389, 277-91	14
260	Tetracyclines cause cell stress-dependent ATF4 activation and mTOR inhibition. 2014 , 320, 281-9	25
259	Minocycline mechanism of neuroprotection involves the Bcl-2 gene family in optic nerve transection. 2014 , 124, 755-61	12
258	Effects of caspase-1 knockout on chronic neural recording quality and longevity: insight into cellular and molecular mechanisms of the reactive tissue response. 2014 , 35, 9620-34	85
257	Minocycline inhibits ICAD degradation and the NF- κ B activation induced by 6-OHDA in PC12 cells. 2014 , 1586, 1-11	14
256	Neuroinflammation in Alzheimer's, Parkinson's and Huntington's Diseases. 2014 , 111-150	2
255	Animal models of Huntington's disease for translation to the clinic: best practices. 2014 , 29, 1375-90	59
254	Ghrelin: a link between ageing, metabolism and neurodegenerative disorders. 2014 , 72 Pt A, 72-83	49
253	Microglia in Health and Disease. 2014 ,	9
252	Drosophila Myc, a novel modifier suppresses the poly(Q) toxicity by modulating the level of CREB binding protein and histone acetylation. 2014 , 63, 48-61	18

251	Current preclinical studies on neuroinflammation and changes in blood-brain barrier integrity by MDMA and methamphetamine. 2014 , 87, 125-34	28
250	Suppression of microglial activation is neuroprotective in a mouse model of human retinitis pigmentosa. 2014 , 34, 8139-50	152
249	[Doxycycline or how to create new with the old?]. 2014 , 69, 129-41	1
248	Neuroprotective Effect of Melatonin on Perinatal HypoxiaIschemia. 2014 , 86-97	
247	VGF and striatal cell damage in in vitro and in vivo models of Huntington's disease. 2015 , 3, e00140	9
246	Role of oral Minocycline in acute encephalitis syndrome in India - a randomized controlled trial. 2016 , 16, 67	31
245	Minocycline counter-regulates pro-inflammatory microglia responses in the retina and protects from degeneration. 2015 , 12, 209	83
244	Low concentrations of doxycycline attenuates FasL-induced apoptosis in HeLa cells. 2015 , 48, 38	6
243	N-acetyl-l-tryptophan, but not N-acetyl-d-tryptophan, rescues neuronal cell death in models of amyotrophic lateral sclerosis. 2015 , 134, 956-68	23
242	From demyelination to remyelination: the road toward therapies for spinal cord injury. 2015 , 63, 1101-25	59
241	The role of the immune system in triplet repeat expansion diseases. 2015 , 2015, 873860	22
240	Implication of Caspase-3 as a Common Therapeutic Target for Multineurodegenerative Disorders and Its Inhibition Using Nonpeptidyl Natural Compounds. 2015 , 2015, 379817	36
239	Minocycline protection of neomycin induced hearing loss in gerbils. 2015 , 2015, 934158	3
238	Recent advances in methamphetamine neurotoxicity mechanisms and its molecular pathophysiology. 2015 , 2015, 103969	99
237	An Overview of Potential Targets for Treating Amyotrophic Lateral Sclerosis and Huntington's Disease. 2015 , 2015, 198612	4
236	The immune response of stem cells in subretinal transplantation. 2015 , 6, 161	48
235	Amyloid fibrils are the molecular trigger of inflammation in Parkinson's disease. 2015 , 471, 323-33	106
234	Differential effects of early postinjury treatment with neuroprotective drugs in a mouse model using diffuse reflectance spectroscopy. 2015 , 2, 015001	5

233	Early spatiotemporal characterization of microglial activation in the retinas of rats with streptozotocin-induced diabetes. 2015 , 253, 519-25	23
232	Mechanisms of myocardial ischemia-reperfusion injury and the cytoprotective role of minocycline: scope and limitations. 2015 , 11, 61-76	39
231	Brain tissue responses to neural implants impact signal sensitivity and intervention strategies. 2015 , 6, 48-67	284
230	Mechanisms and potential therapeutic applications of microglial activation after brain injury. 2015 , 21, 309-19	72
229	Preischemic neuroprotective effect of minocycline and sodium ozagrel on transient cerebral ischemic rat model. 2015 , 1599, 85-92	16
228	Minocycline alleviates sevoflurane-induced cognitive impairment in aged rats. 2015 , 35, 585-94	35
227	Brain innate immunity regulates hypothalamic arcuate neuronal activity and feeding behavior. 2015 , 156, 1303-15	47
226	Acute kidney injury after cardiac surgery: is minocycline protective?. 2015 , 28, 193-9	7
225	Minocycline enhances mitomycin C-induced cytotoxicity through down-regulating ERK1/2-mediated Rad51 expression in human non-small cell lung cancer cells. 2015 , 97, 331-40	4
224	How to Stabilize Both the Proteins and the Membranes: Diverse Effects of sHsps in Neuroprotection. 2015 , 527-562	3
223	Minocycline reduces neuroinflammation but does not ameliorate neuron loss in a mouse model of neurodegeneration. 2015 , 5, 10535	32
222	Carcinogenicity assessment of the pan-caspase inhibitor, emricasan, in Tg.rasH2 mice. 2015 , 72, 169-78	7
221	Minocycline reduces spontaneous hemorrhage in mouse models of cerebral amyloid angiopathy. 2015 , 46, 1633-1640	23
220	The microglia in healthy and diseased retina. 2015 , 136, 116-30	72
219	Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington's disease gene carriers. 2015 , 83, 115-21	87
218	Huntington's disease: an update of therapeutic strategies. 2015 , 556, 91-7	46
217	An open-label evaluator-blinded clinical study of minocycline neuroprotection in ischemic stroke: gender-dependent effect. 2015 , 131, 45-50	81
216	Prothrombin Kringle-2: A Potential Inflammatory Pathogen in the Parkinsonian Dopaminergic System. 2016 , 25, 147-55	9

215	Protective Effect of Minocycline Against Ketamine-Induced Injury in Neural Stem Cell: Involvement of PI3K/Akt and Gsk-3 Beta Pathway. 2016 , 9, 135	21
214	Novel Antiplatelet Activity of Minocycline Involves Inhibition of MLK3-p38 Mitogen Activated Protein Kinase Axis. 2016 , 11, e0157115	2
213	miR-196a Ameliorates Cytotoxicity and Cellular Phenotype in Transgenic Huntington's Disease Monkey Neural Cells. 2016 , 11, e0162788	19
212	Neuroinflammation in Synucleinopathies. 2016 , 26, 404-9	37
211	Minocycline Attenuates Kidney Injury in a Rat Model of Streptozotocin-Induced Diabetic Nephropathy. 2016 , 39, 1231-7	16
210	Minocycline exacerbates apoptotic neurodegeneration induced by the NMDA receptor antagonist MK-801 in the early postnatal mouse brain. 2016 , 266, 673-7	10
209	Inflammasome signaling affects anxiety- and depressive-like behavior and gut microbiome composition. 2016 , 21, 797-805	268
208	Minocycline as Adjunctive Treatment to Risperidone in Children with Autistic Disorder: A Randomized, Double-Blind Placebo-Controlled Trial. 2016 , 26, 784-791	27
207	Disrupted mitochondrial genes and inflammation following stroke. 2016 , 166, 139-148	10
206	Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells. 2016 , 137, 782-94	26
205	Is Minocycline an Antiviral Agent? A Review of Current Literature. 2016 , 118, 4-8	10
204	Neuroprotective strategies for NMDAR-mediated excitotoxicity in Huntington's Disease. 2016 , 11, 439-458	1
203	Microglia Activation and Schizophrenia: Lessons From the Effects of Minocycline on Postnatal Neurogenesis, Neuronal Survival and Synaptic Pruning. 2017 , 43, 493-496	43
202	Bee Venom Acupuncture Alleviates Experimental Autoimmune Encephalomyelitis by Upregulating Regulatory T Cells and Suppressing Th1 and Th17 Responses. 2016 , 53, 1419-1445	38
201	Advancing pharmacotherapy for treating Huntington's disease: a review of the existing literature. 2016 , 17, 41-52	22
200	Central nervous system myeloid cells as drug targets: current status and translational challenges. 2016 , 15, 110-24	79
199	Study the efficacy of neuroprotective drugs on brain physiological properties during focal head injury using optical spectroscopy data analysis. 2016 ,	
198	Interactome network analysis identifies multiple caspase-6 interactors involved in the pathogenesis of HD. 2016 , 25, 1600-18	12

197	Minocycline Effectively Protects the Rabbit's Spinal Cord From Aortic Occlusion-Related Ischemia. 2016 , 30, 282-90	3
196	Administration of the glial cell modulator, minocycline, in the nucleus accumbens attenuated the maintenance and reinstatement of morphine-seeking behavior. 2016 , 94, 257-64	25
195	Yeast as a model for the identification of novel survival-promoting compounds applicable to treat degenerative diseases. 2017 , 161, 306-316	9
194	Involvement of Host Defense Mechanisms against <i>Toxoplasma gondii</i> Infection in Anhedonic and Despair-Like Behaviors in Mice. 2017 , 85,	22
193	Early Minocycline and Late FK506 Treatment Improves Survival and Alleviates Neuroinflammation, Neurodegeneration, and Behavioral Deficits in Prion-Infected Hamsters. 2017 , 14, 463-483	15
192	A systematic review on potential mechanisms of minocycline in kidney diseases. 2017 , 69, 602-609	23
191	Protective effect of losartan and ramipril against stress induced insulin resistance and related complications: Anti-inflammatory mechanisms. 2017 , 801, 54-61	5
190	Traumatic Spinal Cord Injury-Repair and Regeneration. 2017 , 80, S9-S22	313
189	Bioprobes. 2017 ,	4
188	Minocycline in Multiple Sclerosis - Compelling Results but Too Early to Tell. 2017 , 376, 2191-2193	4
187	FcR-dependent immune activation initiates astrogliosis during the asymptomatic phase of Sandhoff disease model mice. 2017 , 7, 40518	11
186	The Endocannabinoid System in Local and Systemic Inflammation. 2017 , 9, i-192	1
185	Minocycline attenuates colistin-induced neurotoxicity via suppression of apoptosis, mitochondrial dysfunction and oxidative stress. 2017 , 72, 1635-1645	29
184	Minocycline reduces inflammatory parameters in the brain structures and serum and reverses memory impairment caused by the administration of amyloid β (1-42) in mice. 2017 , 77, 23-31	51
183	Minocycline attenuates sevoflurane-induced cell injury via activation of Nrf2. 2017 , 39, 869-878	16
182	Minocycline treatment suppresses juvenile development and growth by attenuating insulin/TOR signaling in <i>Drosophila</i> animal model. 2017 , 7, 44724	2
181	Therapeutic Strategies in Neurodegenerative Diseases. 2017 , 681-711	
180	Immunotherapies for Movement Disorders: Parkinson Disease and Amyotrophic Lateral Sclerosis. 2017 , 767-797	1

179	Huntington's Disease: Mechanisms of Pathogenesis and Therapeutic Strategies. 2017 , 7,	137
178	Neuroprotective and Neuro-restorative Effects of Minocycline and Rasagiline in a Zebrafish 6-Hydroxydopamine Model of Parkinson's Disease. 2017 , 367, 34-46	39
177	Minocycline attenuates streptomycin-induced cochlear hair cell death by inhibiting protein nitration and poly (ADP-ribose) polymerase activation. 2017 , 656, 83-88	4
176	Phosphorylation of huntingtin at residue T3 is decreased in Huntington's disease and modulates mutant huntingtin protein conformation. 2017 , 114, E10809-E10818	33
175	The inhibitory effect of minocycline on radiation-induced neuronal apoptosis via AMPK β signaling-mediated autophagy. 2017 , 7, 16373	12
174	How good are publicly available web services that predict bioactivity profiles for drug repurposing?. 2017 , 28, 843-862	32
173	Antineuroinflammation of Minocycline in Stroke. 2017 , 22, 120-126	11
172	Laquinimod treatment in the R6/2 mouse model. 2017 , 7, 4947	24
171	Inhibition of colony-stimulating factor 1 receptor early in disease ameliorates motor deficits in SCA1 mice. 2017 , 14, 107	24
170	A small molecule screening to detect potential therapeutic targets in human podocytes. 2017 , 312, F157-F171 8	
169	Minocycline causes widespread cell death and increases microglial labeling in the neonatal mouse brain. 2017 , 77, 753-766	17
168	Postsynaptic density protein transcripts are differentially modulated by minocycline alone or in add-on to haloperidol: Implications for treatment resistant schizophrenia. 2017 , 31, 406-417	13
167	Discovery of Therapeutic Approaches for Polyglutamine Diseases: A Summary of Recent Efforts. 2017 , 37, 860-906	12
166	Restorative Treatments for Spinal Cord Injury. 2017 , 28, 63-71	10
165	Antioxidant-Rich Fraction of Urtica dioica Mediated Rescue of Striatal Mito-Oxidative Damage in MPTP-Induced Behavioral, Cellular, and Neurochemical Alterations in Rats. 2017 , 54, 5632-5645	11
164	Connecting Neuronal Cell Protective Pathways and Drug Combinations in a Huntington's Disease Model through the Application of Quantitative Systems Pharmacology. 2017 , 7, 17803	13
163	Pathogenesis of Huntington's Disease: How to Fight Excitotoxicity and Transcriptional Dysregulation. 2017 ,	1
162	Chaperones in Polyglutamine Aggregation: Beyond the Q-Stretch. 2017 , 11, 145	28

161	Post-translational Modifications and Protein Quality Control in Motor Neuron and Polyglutamine Diseases. 2017 , 10, 82	36
160	Practical considerations for choosing a mouse model of Alzheimer's disease. 2017 , 12, 89	189
159	Antidepressant-Like Actions of Inhibitors of Poly(ADP-Ribose) Polymerase in Rodent Models. 2017 , 20, 994-1004	6
158	Attenuation of neuro-inflammation improves survival and neurodegeneration in a mouse model of severe neonatal hyperbilirubinemia. 2018 , 70, 166-178	22
157	Cause or compensation?-Altered neuronal Ca handling in Huntington's disease. 2018 , 24, 301-310	13
156	Pretreatment with minocycline improves neurogenesis and behavior performance after midazolam exposure in neonatal rats. 2018 , 29, 153-159	15
155	Neuroprotection in Oxidative Stress-Related Neurodegenerative Diseases: Role of Endocannabinoid System Modulation. 2018 , 29, 75-108	55
154	A Retrospective Cohort Analysis Shows that Coadministration of Minocycline with Colistin in Critically Ill Patients Is Associated with Reduced Frequency of Acute Renal Failure. 2018 , 62,	6
153	Cell Death Pathways: a Novel Therapeutic Approach for Neuroscientists. 2018 , 55, 5767-5786	77
152	Minocycline protects developing brain against ethanol-induced damage. 2018 , 129, 84-99	18
151	Immunomodulatory Strategies for Huntington's Disease Treatment. 2017 , 16, 936-944	3
150	Repeated immune activation with low-dose lipopolysaccharide attenuates the severity of Huntington's disease in R6/2 transgenic mice. 2018 , 22, 219-226	5
149	20 Emerging Therapies for Spinal Cord Injury. 2018 ,	
148	New directions in therapeutics for Huntington disease. 2018 , 13, 101-121	13
147	Effects of Therapeutic Hypothermia Combined with Other Neuroprotective Strategies on Ischemic Stroke: Review of Evidence. 2018 , 9, 507-522	12
146	Minocycline for acute stroke treatment: a systematic review and meta-analysis of randomized clinical trials. 2018 , 265, 1871-1879	60
145	Cyanidin-3-glucoside Alleviates 4-Hydroxyhexenal-Induced NLRP3 Inflammasome Activation via JNK-c-Jun/AP-1 Pathway in Human Retinal Pigment Epithelial Cells. 2018 , 2018, 5604610	18
144	Pharmacotherapy in Secondary Progressive Multiple Sclerosis: An Overview. 2018 , 32, 499-526	16

143	Hippo Signaling Pathway Dysregulation in Human Huntington's Disease Brain and Neuronal Stem Cells. 2018 , 8, 11355		33
142	Opioids, gliosis and central immunomodulation. 2018 , 32, 756-767		5
141	Tetracycline repurposing in neurodegeneration: focus on Parkinson's disease. 2018 , 125, 1403-1415		35
140	Tissue-Specific Upregulation of Drosophila Insulin Receptor (InR) Mitigates Poly(Q)-Mediated Neurotoxicity by Restoration of Cellular Transcription Machinery. 2019 , 56, 1310-1329		7
139	The Involvement of NLRP3 on the Effects of Minocycline in an AD-Like Pathology Induced by β Amyloid Oligomers Administered to Mice. 2019 , 56, 2606-2617		21
138	Pro-caspase-3 protects cells from polymyxin B-induced cytotoxicity by preventing ROS accumulation. 2019 , 72, 848-852		8
137	Neuroinflammation and Glial Phenotypic Changes in Alpha-Synucleinopathies. <i>Frontiers in Cellular Neuroscience</i> , 2019 , 13, 263	6.1	42
136	Mutant huntingtin disrupts mitochondrial proteostasis by interacting with TIM23. 2019 , 116, 16593-16602		34
135	Amelioration of the apoptosis-mediated death in isolated human pancreatic islets by minocycline. 2019 , 858, 172518		7
134	Reversal of ultrasonic vocalization deficits in a mouse model of Fragile X Syndrome with minocycline treatment or genetic reduction of MMP-9. 2019 , 372, 112068		8
133	An AIEgen-Peptide Conjugate as a Phototheranostic Agent for Phagosome-Entrapped Bacteria. 2019 , 58, 16229-16235		56
132	An AIEgen-Peptide Conjugate as a Phototheranostic Agent for Phagosome-Entrapped Bacteria. 2019 , 131, 16375-16381		17
131	Demonstration by Infra-Red Imaging of a Temperature Control Defect in a Decompression Sickness Model Testing Minocycline. 2019 , 10, 933		1
130	Minocycline attenuates 3,4-methylenedioxymethamphetamine-induced hyperthermia in the rat brain. 2019 , 858, 172495		2
129	The footprints of mitochondrial impairment and cellular energy crisis in the pathogenesis of xenobiotics-induced nephrotoxicity, serum electrolytes imbalance, and Fanconi's syndrome: A comprehensive review. 2019 , 423, 1-31		25
128	Inflammasomes in neuroinflammatory and neurodegenerative diseases. 2019 , 11,		230
127	The therapeutic role of minocycline in Parkinson's disease. 2019 , 8, 212553		31
126	Combinatory FK506 and Minocycline Treatment Alleviates Prion-Induced Neurodegenerative Events via Caspase-Mediated MAPK-NRF2 Pathway. 2019 , 20,		4

125	Effect of pretreatment with intracerebroventricular injection of minocycline on morphine-induced memory impairment in passive avoidance test: Role of P-CREB and c-Fos expression in the dorsal hippocampus and basolateral amygdala regions. 2019 , 46, 711-722	7
124	Safety and feasibility of minocycline in treatment of acute traumatic brain injury. 2019 , 33, 679-689	15
123	Minocycline attenuates ethanol-induced cell death and microglial activation in the developing spinal cord. 2019 , 79, 25-35	10
122	Methacycline displays a strong efficacy in reducing toxicity in a SCA3 <i>Caenorhabditis elegans</i> model. 2019 , 1863, 279-290	2
121	Identification of a novel caspase cleavage site in huntingtin that regulates mutant huntingtin clearance. 2019 , 33, 3190-3197	12
120	Conditioned medium from amniotic cells protects striatal degeneration and ameliorates motor deficits in the R6/2 mouse model of Huntington's disease. 2019 , 23, 1581-1592	26
119	The Effect of Minocycline on Fat Graft Survival and Apoptotic Pathway. 2019 , 35, 96-102	11
118	Minocycline prevents the development of depression-like behavior and hippocampal inflammation in a rat model of Alzheimer's disease. 2019 , 236, 1281-1292	25
117	Pathology, Prevention and Therapeutics of Neurodegenerative Disease. 2019 ,	1
116	Treatment Paradigms in Huntington's Disease. 2019 , 191-196	1
115	Are immunotherapies for Huntington's disease a realistic option?. 2019 , 24, 364-377	14
114	Neuroprotective Effects of Doxycycline in the R6/2 Mouse Model of Huntington's Disease. 2020 , 57, 1889-1903	20
113	Microglial depletion prevents extracellular matrix changes and striatal volume reduction in a model of Huntington's disease. 2020 , 143, 266-288	40
112	Chronic minocycline treatment exerts antidepressant effect, inhibits neuroinflammation, and modulates gut microbiota in mice. 2020 , 237, 3201-3213	13
111	Role of CGRP in Neuroimmune Interaction via NF- κ B Signaling Genes in Glial Cells of Trigeminal Ganglia. 2020 , 21,	2
110	Minocycline reduces inflammatory response and cell death in a S100B retina degeneration model. 2020 , 17, 375	11
109	Constructing and evaluating caspase-activatable adeno-associated virus vector for gene delivery to the injured heart. 2020 , 328, 834-845	1
108	A single administration of the antibiotic, minocycline, reduces fear processing and improves implicit learning in healthy volunteers: analysis of the serum metabolome. 2020 , 10, 148	6

107	Validation of behavioral phenotypes in the BACHD rat model. 2020 , 393, 112783	1
106	Genotoxic effect of non-lethal concentrations of minocycline in human glial cell culture. 2020 , 128, 110285	2
105	Immunotherapies in Huntington's disease and Synucleinopathies. 2020 , 11, 337	6
104	Fragile X clinical features and neurobiology. 2020 , 351-375	
103	Therapeutic Advances for Huntington's Disease. <i>Brain Sciences</i> , 2020 , 10,	3-4 27
102	Osmolytes: A Possible Therapeutic Molecule for Ameliorating the Neurodegeneration Caused by Protein Misfolding and Aggregation. 2020 , 10,	15
101	TGF- β Provides Neuroprotection via Inhibition of Microglial Activation in 3-Acetylpyridine-Induced Cerebellar Ataxia Model Rats. 2020 , 14, 187	5
100	Tolerance-inducing effect and properties of innate immune stimulation on chronic stress-induced behavioral abnormalities in mice. 2021 , 91, 451-471	13
99	Minocycline for the management of multiple sclerosis: repositioning potential, opportunities, and challenges. 2021 , 21, 35-43	3
98	Minocycline in neurodegenerative and psychiatric diseases: An update. 2021 , 28, 1056-1081	14
97	Ubiquitination and the proteasome rather than caspase-3-mediated C-terminal cleavage are involved in the EAAT2 degradation by staurosporine-induced cellular stress. 2021 , 157, 1284-1299	1
96	Antibiotics with therapeutic effects on spinal cord injury: a review. 2021 , 35, 277-304	1
95	Tetracycline and viruses: a possible treatment for COVID-19?. 2021 , 166, 1-7	19
94	Neuroimmune crosstalk and evolving pharmacotherapies in neurodegenerative diseases. 2021 , 162, 160-178	5
93	Physiology of cellular demise: Apoptosis, necrosis, and autophagy. 2021 , 23-78	
92	Huntington disease. 2021 , 371-400.e14	
91	Neuroimaging, Urinary, and Plasma Biomarkers of Treatment Response in Huntington's Disease: Preclinical Evidence with the p75 Ligand LM11A-31. 2021 , 18, 1039-1063	4
90	Inhibition of Caspase-1 with Tetracycline Ameliorates Acute Lung Injury. 2021 , 204, 53-63	10

89	Minocycline Mitigation of Tremor Syndrome and Defect of Cognitive and Balance Induced by Harmaline.. 2021 , 12, 255-268	0
88	Anti-tuberculotic thionamide antibiotics show antioxidative and neuronal cytoprotective nature by inhibiting amyloid formation in human insulin and amyloid β 2. 2021 , 326, 115396	5
87	Neuroprotective effect of minocycline against acute brain injury in clinical practice: A systematic review. 2021 , 86, 50-57	4
86	Tetraciclinas: ¿Antibióticos de uso potencial en la COVID-19?. 62, 69-84	
85	Oral Minocycline Therapy Improves Symptoms of Myalgic Encephalomyelitis, Especially in the Initial Disease Stage. 2021 , 60, 2577-2584	1
84	Effectiveness of Immunotherapies for Psychotic Disorders. 2021 , 96-108	
83	Two hit mitochondrial-driven model of synapse loss in neurodegeneration. 2021 , 158, 105451	4
82	Neuroinflammation in Huntington's Disease. 2014 , 179-197	1
81	Apoptosis in Neurodegenerative Diseases. 2009 , 479-504	1
80	The Current Status of Neuroprotection for Spinal Cord Injury. 2017 , 529-583	2
79	Changes of blood-brain barrier permeability following intracerebral hemorrhage and the therapeutic effect of minocycline in rats. 2011 , 110, 61-7	19
78	Huntington Disease. 2007 , 369-392	3
77	Key driver genes as potential therapeutic targets in renal allograft rejection. 2020 , 5,	5
76	Induction of neostriatal neurogenesis slows disease progression in a transgenic murine model of Huntington disease. 2007 , 117, 2889-902	109
75	Treadmill exercise enhances spatial learning ability through suppressing hippocampal apoptosis in Huntington's disease rats. 2015 , 11, 133-9	16
74	Minocycline inhibits alkali burn-induced corneal neovascularization in mice. 2012 , 7, e41858	27
73	Attenuation of pathogenic immune responses during infection with human and simian immunodeficiency virus (HIV/SIV) by the tetracycline derivative minocycline. 2014 , 9, e94375	8
72	Minocycline promotes the generation of dendritic cells with regulatory properties. 2016 , 7, 52818-52831	12

71	Minocycline treatment increases resistance to oxidative stress and extends lifespan in via FOXO. 2017 , 8, 87878-87890	14
70	Consideration of a Pharmacological Combinatorial Approach to Inhibit Chronic Inflammation in Alzheimer's Disease. 2019 , 16, 1007-1017	2
69	Neuroprotective Effects of Combined Treatment with Minocycline and Olfactory Ensheathing Cells Transplantation against Inflammation and Oxidative Stress after Spinal Cord Injury. 2019 , 21, 220-228	5
68	Minocycline for negative symptoms of schizophrenia and possible mechanistic actions: the BeneMin RCT. 2019 , 6, 1-66	1
67	Protective Effect of Minocycline Against Cisplatin-induced Ototoxicity. 2011 , 4, 77-82	19
66	Minocycline targets multiple secondary injury mechanisms in traumatic spinal cord injury. 2017 , 12, 702-713	67
65	Promises and pitfalls of immune-based strategies for Huntington's disease. 2017 , 12, 1422-1425	6
64	Minocycline for Schizophrenia: A critical review. 2012 , 02, 399-406	4
63	Burn-induced distant organ injury in rats and the effect of minocycline. 2017 , 30, 137-145	1
62	Minocycline fails to improve neurologic and histologic outcome after ventricular fibrillation cardiac arrest in rats. 2019 , 8, 106-119	4
61	Zebrafish an experimental model of Huntington's disease: molecular aspects, therapeutic targets and current challenges. 2021 , 48, 8181-8194	2
60	Therapeutics in Huntington's Disease. 2002 , 447-491	1
59	[Pre-symptomatic diagnosis of severe hereditary diseases with late onset in Lebanon: a choice or a necessity?]. 2005 , 17, 617-26	
58	Cytokines and Neurodegeneration. 2005 , 163-191	
57	Huntington's Disease. 2005 , 351-376	
56	Minocycline in Cerebral Ischemia and Excitotoxicity. 2007 , 255-267	
55	Huntington's Disease: Unraveling the Pathophysiological Cascade Behind a Singular Gene Defect. 2007 , 167-188	
54	Adjunctive Therapy for Long-Term Support of Cognitive Impairment. 2009 , 249-266	

53	Murine models of Huntington disease. 2009 , 4, 617-638	
52	The Effect of Swimming and Minocycline on Motor Function and Expression of Bcl-2 after Spinal Cord Injury in the Rats. 2009 , 19, 1489-1494	
51	Ischemia and Stroke. 2014 , 413-435	1
50	Apoptosis and Autophagy. 2017 , 75-113	1
49	Burn-induced distant organ injury in rats and the effect of minocycline.	
48	Huntington's Disease and Other Polyglutamine Repeat Diseases: Molecular Mechanisms and Pathogenic Pathways. 2018 , 145-188	
47	Investigating anti-neuroinflammatory mechanism of orientin in lipopolysaccharide-induced BV2 microglia cells. 78-92	
46	Microglia-specific overexpression of β -synuclein leads to severe dopaminergic neurodegeneration by phagocytic exhaustion and oxidative toxicity. 2021 , 12, 6237	10
45	Novel Therapeutic Challenges in Cerebellar Diseases. 2020 , 1-33	1
44	Fragile X clinical features and neurobiology. 2020 , 311-332	
43	The paradigm of Huntington's disease: Therapeutic opportunities in neurodegeneration. 2004 , 1, 128-138	
42	Using advances in neuroimaging to detect, understand, and monitor disease progression in Huntington's disease. 2004 , 1, 263-272	
41	Translating therapies for Huntington's disease from genetic animal models to clinical trials. 2004 , 1, 298-306	1
40	Therapeutic perspectives for the treatment of Huntington's disease: treating the whole body. 2008 , 23, 237-50	38
39	Neuroimmune interactions and pain: focus on glial-modulating targets. 2008 , 9, 726-34	83
38	Minocycline delayed photoreceptor death in rds mice through iNOS-dependent mechanism. 2007 , 13, 1073-82	23
37	Minocycline and sulforaphane inhibited lipopolysaccharide-mediated retinal microglial activation. 2007 , 13, 1083-93	33
36	Potential of immunosuppressive agents in cerebral ischaemia. 2011 , 133, 15-26	6

35	Effects of minocycline on expression of bcl-2, bax in early retinal neuropathy of diabetes in rats. 2011 , 4, 162-4	2
34	Minocycline attenuates cirrhotic cardiomyopathy and portal hypertension in a rat model: Possible involvement of nitric oxide pathway. 2016 , 19, 1222-1230	3
33	The anti-inflammatory effect of minocycline on endotoxin-induced uveitis and retinal inflammation in rats. 2019 , 25, 359-372	8
32	fMRI biomarker of early neuronal dysfunction in presymptomatic Huntington's Disease. 2004 , 25, 1715-21	166
31	Non-Cell Autonomous and Epigenetic Mechanisms of Huntington's Disease. 2021 , 22,	2
30	Novel Therapeutic Challenges in Cerebellar Diseases. 2022 , 2667-2699	
29	Inflammasome Signaling in the Aging Brain and Age-Related Neurodegenerative Diseases.. 2022 , 1	2
28	Recent developments in the management of Huntington's disease.. 2022 , 120, 105642	2
27	Tetracycline ameliorates silica-induced pulmonary inflammation and fibrosis via inhibition of caspase-1.. 2022 , 23, 21	0
26	Neuroprotection against neurodegenerative diseases: development of a novel hybrid neuroprotective peptide Colivelin. 2007 , 35, 55-84	8
25	Challenges of repurposing tetracyclines for the treatment of Alzheimer's and Parkinson's disease.. 2022 , 1	2
24	Clinical trials. 2022 , 411-440	
23	Targeting Microglia to Treat Degenerative Eye Diseases.. 2022 , 13, 843558	1
22	Revisiting Minocycline in Intracerebral Hemorrhage: Mechanisms and Clinical Translation.. 2022 , 13, 844163	0
21	Minocycline treatment improves proteostasis during Drosophila aging via autophagy mediated by FOXO and Hsp70.. 2022 , 149, 112803	0
20	Neuroinflammation in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia and the Interest of Induced Pluripotent Stem Cells to Study Immune Cells Interactions With Neurons.. 2021 , 14, 767041	3
19	AAV Vector-Mediated Antibody Delivery (A-MAD) in the Central Nervous System.. 2022 , 13, 870799	
18	Blue Light Induces RPE Cell Necroptosis, Which Can Be Inhibited by Minocycline.. <i>Frontiers in Medicine</i> , 2022 , 9, 831463	4-9

17	Antidepressant-like Effects of Renin Inhibitor Aliskiren in an Inflammatory Mouse Model of Depression. <i>Brain Sciences</i> , 2022 , 12, 655	3.4	
16	Mitochondria-Related Apoptosis Regulation by Minocycline: A Study on a Transgenic Drosophila Model of Alzheimer's Disease. <i>ACS Omega</i> ,	3.9	
15	Tetracyclines: An Important Therapeutic Tool for Dermatologists. <i>International Journal of Environmental Research and Public Health</i> , 2022 , 19, 7246	4.6	○
14	Glial Cells and Brain Diseases: Inflammasomes as Relevant Pathological Entities. <i>Frontiers in Cellular Neuroscience</i> , 16,	6.1	○
13	Microglia in multiple sclerosis: Pathogenesis and imaging. <i>Current Opinion in Neurology</i> , 2022 , 35, 299-306	6.1	1
12	Therapeutic Strategies in Huntington's Disease: From Genetic Defect to Gene Therapy. 2022 , 10, 1895		○
11	Inflammasome activation and assembly in Huntington's disease. 2022 , 151, 134-142		○
10	Effect of minocycline and its nano-formulation on central auditory system in blast-induced hearing loss rat model. 2022 ,		2
9	Systematic Review of the Therapeutic Role of Apoptotic Inhibitors in Neurodegeneration and Their Potential Use in Schizophrenia. 2022 , 11, 2275		○
8	The contribution of an imbalanced redox signalling to neurological and neurodegenerative conditions. 2023 , 194, 71-83		○
7	SARS-CoV-2 induces cytokine storm/hyperinflammatory responses in RA patients through pyroptosis. 13,		○
6	Minocycline treatment improves cognitive and functional plasticity in a preclinical mouse model of major depressive disorder. 2023 , 114295		1
5	Repurposing sarecycline for osteoinductive therapies: an in vitro and ex vivo assessment.		○
4	Neurodegeneration, Mitochondria, and Antibiotics. 2023 , 13, 416		○
3	Neuromodulatory effect of 4-(methylthio)butyl isothiocyanate against 3-nitropropionic acid induced oxidative impairments in human dopaminergic SH-SY5Y cells via BDNF/CREB/TrkB pathway. 2023 , 13,		○
2	Treatments for diabetic retinopathy and diabetic macular edema in pipeline. 2024 , 215-263		○
1	Apoptotic cell death in disease: Current understanding of the NCCD 2023. 2023 , 30, 1097-1154		○